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1 Abstract		
Background:	 Cardiovascular	 disease	 (CVD)	 represents	 a	major	 health	 burden	and	 is	 the	 world’s	 leading	 cause	 of	 mortality.	 The	 most	 common	 pathological	conditions	 in	 CVD	 are	 endothelial	 dysfunction	 and	 atherosclerosis.	 The	 most	frequent	 complication	 is	 arterial	 thrombosis,	 which	 may	 lead	 to	 myocardial	infarction	 and	 stroke.	 Atherogenesis	 is	 characterised	 by	 the	 occurrence	 of	chronic	 inflammatory	 processes	 and	 involvement	 of	 reactive	 oxygen	 species	(ROS).	 Recently,	 ROS-mediated	 formation	 of	 neutrophil	 extracellular	 traps	(NETs)	 was	 associated	 with	 atherothrombosis	 and	 subsequent	 major	 adverse	cardiovascular	events.	Sirtuins	are	a	 family	of	seven	NAD+-dependent	protein	deacetylases	 that	play	a	beneficial	role	 in	metabolism	and	age-related	processes	and	are	activated	upon	caloric	restriction.	Sirtuin	3	(Sirt3)	is	located	in	mitochondria,	where	it	governs	mitochondrial	metabolism.	Mitochondria	are	major	producers	of	ROS	and	Sirt3	protects	the	cell	from	ROS	by	activating	superoxide	dismutase	2	(SOD2)	and	by	increasing	 transcription	 of	 SOD2	 and	 Catalase,	 the	 main	 mitochondrial	 ROS	scavengers.	 Sirtuin	 6	 (Sirt6)	 is	 located	 in	 the	 nucleus,	 where	 it	 regulates	inflammation,	DNA	maintenance,	and	glucose	and	lipid	metabolism.	Sirt6	inhibits	inflammation	by	interacting	with	subunits	of	nuclear	factor	kappa	B	(NF-κB)	and	activator	protein	1	(AP-1)	and	subsequently	deacetylating	lysine	9	of	Histone	3	(H3K9)	 to	 attenuate	 NF-κB-	 and	 AP-1-mediated	 transcription	 of	 pro-inflammatory	genes.	Current	studies	suggest	that	this	mechanism	may	also	occur	in	endothelial	cells.	NF-κB	and	AP-1	also	regulate	the	expression	of	tissue	factor	(TF),	a	central	initiator	of	blood	coagulation.	Of	note,	the	functions	of	Sirt3	in	atherosclerosis	and	endothelial	function,	as	well	as	 the	 roles	 of	 Sirt3	 and	 Sirt6	 in	 arterial	 thrombosis,	 have	 not	 yet	 been	investigated.		
Methods:	Sirt3-deficient	(Sirt3-/-)	mice	were	used	to	investigate	the	causal	role	of	 Sirt3	 in	 vascular	 disease.	 For	 assessing	 atherosclerosis,	 Sirt3-/-	 mice	 were	crossbred	with	 low-density	 lipoprotein	 receptor	 (LDL-R)	depleted	mice	 and	8-week-old	males	were	 fed	a	1.25%	(w/w)	high-cholesterol	diet	 for	12	weeks	 to	induce	 atherosclerosis.	 Atherosclerosis	 was	 evaluated	 in	 thoracoabdominal	aortae	 en	 face	and	 in	 cross	 sections	 of	 aortic	 roots.	 In	 addition,	metabolic	 rate	and	 systemic	 oxidative	 stress	 were	 assessed	 using	 indirect	 calorimetry	 and	quantification	of	the	oxidative	stress	marker	malondialdehyde.	To	 induce	 endothelial	 dysfunction,	 8-week-old	 Sirt3-/-	 mice	 were	 fed	 a	 1.25%	(w/w)	 high-cholesterol	 diet	 for	 12	 weeks.	 Subsequently,	 aortic	 rings	 were	isolated	 and	 endothelium-dependent	 relaxation	 assessed	 in	 an	 organ	 chamber	bath.	Molecular	effects	of	Sirt3	deficiency	were	analysed	using	a	siRNA-mediated	knockdown	of	Sirt3	in	cultured	human	aortic	endothelial	cells	(HAECs).		For	 thrombosis	 experiments,	 16-week-old	 Sirt3-/-	 mice	 were	 stimulated	 by	 an	intraperitoneal	 injection	of	5	mg/kg	 lipopolysaccharide	(LPS).	To	 investigate	 in	
vivo	 time	to	 thrombotic	occlusion,	mice	were	subjected	to	 laser-induced	 in	vivo	carotid	 thrombosis.	To	examine	ex	vivo	clotting	properties,	blood	was	analysed	using	 rotational	 thromboelastometry	 (ROTEM).	 Moreover,	 neutrophils	 were	isolated	from	bone	marrow	and	stimulated	with	LPS	to	assess	formation	of	NETs.	
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CD14+	 leukocytes	 from	 patients	 suffering	 from	 acute	 ST-elevation	 myocardial	infarction	(STEMI)	were	analysed	for	transcription	levels	of	Sirt3	and	SOD2.		Finally,	endothelium-specific	Sirt6	deletion	in	mice	was	generated	using	the	VE-cadherin	promoter	 and	 carotid	 thrombosis	was	 induced	 as	 described	 above	 to	investigate	 the	 effects	 of	 endothelial	 Sirt6	 loss-of-function	 in	 thrombosis.	 To	study	 the	 molecular	 effects	 of	 Sirt6	 deficiency	 on	 endothelial	 cells,	 Sirt6	knockdown	was	performed	in	cultured	HAECs.		
Results:	Absence	of	Sirt3	did	not	affect	atherosclerosis	but	 increased	systemic	oxidative	 stress,	 accelerated	 weight	 gain	 and	 impaired	 adaptation	 to	 rapid	changes	in	nutrient	supply.		Loss	of	Sirt3	caused	mild	endothelial	dysfunction	and	increased	oxidative	stress	in	endothelial	cells.	Sirt3-deficient	HAECs	were	protected	from	ROS-induced	cell	death	 via	 a	 C/EBP-β-dependent	 rescue	mechanism	 that	 induced	 expression	 of	SOD2.		Time	 to	 thrombotic	 carotid	 occlusion	 was	 cut	 in	 half	 in	 Sirt3-/-	 mice.	 Clot	formation	 was	 accelerated	 and	 clot	 stability	 increased	 compared	 to	 controls.	Furthermore,	increased	levels	of	active	soluble	TF	were	measured	in	the	blood	of	Sirt3-/-	 mice.	 In	 neutrophils,	 Sirt3	 deletion	 decreased	 SOD2	 transcription	 and	increased	 NET	 formation.	 In	 parallel,	 leukocytes	 of	 STEMI	 patients	 exhibited	reduced	transcription	of	Sirt3	and	SOD2.		Specific	 deletion	 of	 Sirt6	 in	 mouse	 endothelium	 decreased	 time	 to	 carotid	thrombotic	occlusion	by	45%.	In	 line	with	these	 in	vivo	 findings,	knockdown	of	Sirt6	in	HAECs	increased	transcription	of	pro-inflammatory	targets	of	NF-κB	and	AP-1	as	well	as	amount	and	activity	of	TF.		
Conclusions:	Deletion	 of	 Sirt3	 increases	 systemic	 and	 cellular	 ROS	 levels,	 and	soluble	TF	 levels	 in	 the	blood,	and	 thus	 favours	development	of	cardiovascular	metabolic	risk	factors,	endothelial	dysfunction,	and	arterial	thrombosis.	Endothelium-specific	 deletion	 of	 Sirt6	 accelerates	 arterial	 thrombosis	 by	 an	increase	 in	 pro-inflammatory	 signalling,	 increased	 TF	 presence	 and	 activity	 in	endothelial	cells.		These	results	suggest	that	endogenous	Sirt3	and	Sirt6	bear	the	potential	to	aid	in	the	 prevention	 of	 endothelial	 dysfunction,	 and	 arterial	 thrombosis	 and	 make	them	interesting	targets	for	future	therapeutic	testing.		 	
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2 Zusammenfassung		
Hintergrund:	 Kardiovaskuläre	 Krankheiten	 (KVK)	 stellen	 eine	 massive	Gesundheitsbelastung	 dar	 und	 sind	 weltweit	 die	 Haupttodesursache.	 Die	 am	häufigsten	 auftretenden	 Krankheitserscheinungen	 bei	 KVK	 sind	 endotheliale	Dysfunktion	 und	 Arteriosklerose.	 Die	 häufigste	 Komplikation	 ist	 arterielle	Thrombose,	die	zu	einem	Herzinfarkt	oder	Schlaganfall	führen	kann.	Die	Bildung	von	 Arteriosklerose	 wird	 typischerweise	 von	 Entzündungsreaktionen	 und	 der	Formation	von	 reaktiven	Sauerstoffspezies	 (RSS)	begleitet.	Unlängst	wurde	die	Bildung	 sogenannter	 neutrophil	 extracellular	 traps	 (deutsch:	 neutrophile	extrazelluläre	 Fallen,	 NETs)	 in	 Zusammenhang	 mit	 KVK	 und	 ihren	 negativen	Folgeerscheinungen	gebracht.	Die	 Sirtuine	 sind	 eine	 Proteinfamilie	 bestehend	 aus	 sieben	 NAD+-abhängigen	Deacetylasen.	Sie	werden	durch	Kalorienrestriktion	aktiviert	und	haben	wichtige	vorteilhafte	 Funktionen	 im	 Stoffwechsel	 und	 bei	 altersbedingten	 Krankheiten.	Sirtuin	 3	 (Sirt3)	 befindet	 sich	 in	 den	 Mitochondrien,	 wo	 es	 den	 dortigen	Stoffwechsel	 steuert.	 Mitochondrien	 sind	 Haupterzeuger	 von	 RSS	 und	 Sirt3	beschützt	 die	 Zelle	 vor	 diesen	 reaktiven	 Substanzen	 in	 dem	 es	Superoxiddismutase	 2	 (SOD2)	 aktiviert	 und	 die	 Transkription	 von	 SOD2	 und	Catalase,	 den	 zwei	 wichtigsten	 RSS-Inaktivatoren	 in	 Mitochondrien,	 fördert.	Sirtuin	 6	 (Sirt6)	 befindet	 sich	 im	 Zellkern	 und	 reguliert	 dort	Entzündungsreaktionen,	 Reparatur	 von	 DNS-Schäden,	 sowie	 Glukose-	 und	Fettmetabolismus.	Sirt6	hemmt	Entzündungen	in	dem	es	mit	Untereinheiten	von	Nuklearem	 Faktor	 kappa	 B	 (NF-κB)	 und	 Aktivatorprotein	 1	 (AP-1)	 interagiert	und	anschliessend	Lysin	9	an	Histon	3	(H3K9)	deacetyliert,	was	die	NF-κB	und	AP-1	 bedingte	 Transkription	 entzündungsfördernder	 Gene	 bremst.	 Aktuelle	Studien	 suggerieren,	 dass	 dieser	 Mechanismus	 auch	 in	 Endothelzellen	 abläuft.	NF-κB	 und	 AP-1	 regulieren	 ausserdem	 die	 Expression	 von	 Tissue	 Factor	(deutsch:	Gewebefaktor;	TF),	einem	Hauptinitiator	der	Blutkoagulation.	Die	Bedeutung	von	Sirt3	 in	Arteriosklerose	und	Endotheldysfunktion	sowie	die	Rolle	von	Sirt3	und	Sirt6	in	arterieller	Thrombose	sind	bisher	nicht	bekannt.		
Methoden:	Die	Rolle	von	Sirt3	in	KVK	wurde	in	Mäusen	mit	einem	Sirt3-Defizit	(Sirt3-/-)	untersucht.	Um	einen	Effekt	auf	Arteriosklerose	evaluieren	zu	können,	wurden	 Sirt3-/--Mäuse	 mit	 zusätzlicher	 Deletion	 des	 low-density	 lipoprotein	(Lipoprotein	mit	 niedriger	 Dichte)	 Rezeptors	 (LDL-R)	 gezüchtet	 und	 ab	 einem	Alter	 von	 8	 Wochen	 für	 12	 Wochen	 mit	 einer	 cholesterinreichen	 Nahrung	(1.25%	 Cholesterin	 (w/w))	 gefüttert,	 um	 Arteriosklerose	 zu	 verursachen.	Arteriosklerose	wurde	 in	 thorakoabdominellen	Aortae	en	face	und	 in	Schnitten	von	 Aortenwurzeln	 beurteilt.	 Zusätzlich	 wurde	 die	 Stoffwechselrate	 und	systemischer	 oxidativer	 Stress	 mittels	 indirekter	 Kalorimetrie	 und	Quantifizierung	des	oxidativen	Stressmarkers	Malondialdehyd	gemessen.	Weiterhin	 wurden	 8	 Wochen	 alte	 Sirt3-/--Mäuse	 für	 12	 Wochen	 mit	 einer	cholesterinreichen	 Nahrung	 gefüttert	 um	 die	 Endothelfunktion	 zu	beeinträchtigen.	Aortenringe	wurden	isoliert	und	endothelabhängige	Relaxation	in	einem	Organbad	getestet.	Um	molekulare	Auswirkungen	eines	Sirt3-Verlustes	zu	 untersuchen,	 wurde	 in	 menschlichen	 Aortaendothelzellen	 (MAEZs)	 mittels	kleiner	RNS-Fragmente	die	Sirt3-Proteinexpression	gehemmt.	
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Zur	 Untersuchung	 von	 arterieller	 Thrombose	wurden	 16	Wochen	 alte	 Sirt3-/--Mäuse	 intraperitoneal	mit	5	mg/kg	Lipopolysaccharid	 (LPS)	 injiziert.	 In	diesen	Mäusen	 wurde	 daraufhin	 mittels	 Laserbestrahlung	 Thrombose	 in	 der	 rechten	Karotis	 ausgelöst,	 und	 die	 Zeit	 bis	 zum	 thrombotischen	 Verschluss	 in	 vivo	gemessen.	 Das	 Blut	 der	 Sirt3-/--Mäuse	 wurde	 mittels	 Thromboelastometrie	(ROTEM)	 ex	 vivo	 auf	 seine	 Gerinnungseigenschaften	 untersucht.	 Zusätzlich	wurden	Neutrophile	aus	dem	Knochenmark	der	Mäuse	isoliert	und	mit	LPS	zur	Bildung	 von	 NETs	 angeregt.	 CD14+-Leukozyten	 aus	 Patienten,	 die	 an	 einem	akuten	Myokardinfarkt	mit	ST-Hebung	(STEMI)	litten	wurden	auf	Transkription	von	Sirt3	und	SOD2	getestet.	Abschliessend	 wurde	 unter	 Verwendung	 des	 vaskulären	 endothelialen	Cadherinpromotors	 eine	 endothelzellspezifische	 Deletion	 von	 Sirt6	 in	 Mäusen	generiert,	 in	denen	wie	beschrieben	Thrombose	ausgelöst	wurde,	um	die	Rolle	von	 endothelialem	 Sirt6	 in	 dieser	 Erkrankung	 zu	 studieren.	 Um	 Effekte	 auf	molekularer	 Ebene	 zu	 untersuchen	 wurde	 die	 Sirt6-Expression	 in	 HAECs	unterdrückt.		
Ergebnisse:	 Arteriosklerose	war	 in	 Abwesenheit	 von	 Sirt3	 nicht	 verändert.	 In	Sirt3-/--Mäusen	 konnten	 allerdings	 erhöhte	 Werte	 systemischen	 oxidativen	Stresses,	 beschleunigte	 Gewichtszunahme	 und	 schlechte	 Anpassung	 an	Veränderungen	im	Nahrungsangebot	festgestellt	werden.	In	Endothelzellen	verursachte	der	Sirt3-Verlust	erhöhten	oxidativen	Stress,	und	schwache	endotheliale	Dysfunktion.	Ein	C/EBP-β-abhängiger	Mechanismus,	der	SOD2-Expression	induzierte,	schützte	HAECs	vor	Zelltod	durch	erhöhte	RSS.	Die	thrombotische	Verschlusszeit	in	Sirt3-/--Mäusen	verkürzte	sich	im	Vergleich	zu	 Kontrolltieren	 um	 die	 Hälfte	 einhergehend	 mit	 einer	 beschleunigten	Gerinnselbildung	und	erhöhter	Gerinnselstabilität.	Ausserdem	konnten	erhöhte	TF-Spiegel	 im	 Blut	 der	 Sirt3-/--Mäuse	 gemessen	 werden.	 Deletion	 von	 Sirt3	 in	Neutrophilen	verringerte	die	Transkription	von	SOD2	und	erhöhte	die	Bildung	von	 NETs.	 Parallel	 dazu	 zeigten	 Leukozyten	 von	 STEMI-Patienten	 eine	verringerte	Gentranskription	von	Sirt3	und	SOD2.		Fehlendes	 Sirt6	 in	Endothelzellen	 verringerte	die	 Zeit	 bis	 zum	 thrombotischen	Verschluss	der	Karotis	in	Mäusen	um	45%.	Entsprechend	dieser	Beobachtungen	
in	 vivo	 zeigte	 sich	 in	 HAECs	 mit	 verringerter	 Sirt6-Expression	 eine	 erhöhte	Menge	und	Aktivität	von	TF,	sowie	eine	Aktivierung	NF-κB	und	AP-1	regulierter,	entzündungsfördernder	Gene.		
Schlussfolgerungen:	Deletion	von	Sirt3	erhöht	systemische	sowie	zelluläre	RSS	und	 TF-Spiegel	 im	 Blut	 und	 fördert	 daher	 die	 Entwicklung	 kardiovaskulärer	Risikofaktoren,	endotheliale	Dysfunktion	und	arterielle	Thrombose.	Endothelzellspezifisches	 Fehlen	 von	 Sirt6	 beschleunigt	 arterielle	 Thrombose	durch	 Entzündungsreaktionen	 und	 erhöht	 Präsenz	 und	 Aktivität	 von	 TF	 in	Endothelzellen.	Die	Resultate	suggerieren,	dass	endogenes	Sirt3	und	Sirt6	das	Potential	in	sich	tragen	in	der	Prävention	und	akuten	Versorgung	endothelialer	Dysfunktion	und	arterieller	Thrombose	unterstützend	zu	wirken.	Dies	macht	sie	zu	interessanten	Kandidaten	für	zukünftige	therapeutische	Tests.	 	
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4 Introduction	
4.1 Relevance	of	cardiovascular	disease	Cardiovascular	 disease	 (CVD)	 is	 the	 leading	 cause	 of	 death	worldwide	 (Figure	
1).1	 Between	 2005	 and	 2015,	 the	 number	 of	 global	 CVD	 deaths	 increased	 by	12.5%	to	a	total	number	of	17.9	million	deaths	in	2015.	More	than	85%	of	these	deaths	were	caused	by	ischemic	heart	disease	and	stroke.2	Interestingly,	an	age-standardisation	 of	 cardiovascular	 deaths	 in	 the	 past	 decade	 shows,	 that	 the	global	 burden	 of	 cardiovascular	 mortality	 in	 relation	 to	 the	 total	 world	population	 decreased	 by	 15.6%.2	 This	 may	 mainly	 be	 due	 to	 the	 fact	 that	cardiovascular	 care	 is	 improving,	but	 cannot	keep	pace	with	 the	growth	of	 the	global	population.3,4	At	 the	 same	 time,	however,	many	 risk	 factors	 for	CVD	are	increasing,	particularly	obesity,	diabetes	mellitus,	and	age.5-7	Thus,	in	the	future,	the	prevalence	of	CVD	is	likely	to	rise	again	and	the	costs	for	treatment	will	grow	substantially.8,9	 This	 emphasises	 the	 urgent	 need	 for	 novel	 strategies	 to	effectively	prevent	CVD.		
Figure	 1.	 Top	 10	 causes	 of	 death	 globally	 2015.	 Source:	 World	 Health	 Organisation	
(http://www.who.int/mediacentre/factsheets/fs310/en/).		
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4.2 The	endothelium	
Arterial	wall	The	 normal	 arterial	 vessel	 wall	 consists	 of	 three	 layers	 (Figure	 2).	 The	outermost	 layer	 of	 the	 wall,	 the	 tunica	 externa	 (externa),	 mainly	 consists	 of	connective	 tissue	 like	 collagen,	 which	 stabilizes	 and	 anchors	 the	 vessel	 to	surrounding	 organs.	 The	 middle	 layer,	 the	 tunica	 media	 (media),	 is	 mainly	 a	smooth	 muscle	 cell	 (SMC)	 layer	 and	 is	 separated	 from	 the	 externa	 by	 the	external	 elastic	membrane.	 Contraction	 of	 the	 SMCs	 regulates	 vessel	 diameter,	determines	 regional	 blood	 flow,	 and	 systemic	 blood	 pressure.	 The	 innermost	layer	 of	 an	 artery,	 the	 tunica	 intima	 (intima),	 consists	 of	 endothelial	 cells	supported	by	the	internal	elastic	membrane.		
Figure	 2.	 Structure	 of	 the	 vascular	wall.	 Adapted	from	Pearson	Education,	2011	and	‘Medical	
Gallery	of	Blouse	Medical	2014’.10		
Function	of	the	endothelium	The	endothelium	is	a	cell	monolayer,	which	physically	separates	the	blood	from	the	 rest	of	 the	vessel.	As	opposed	 to	other	 tissues,	 it	has	 the	unique	 feature	 to	maintain	 blood	 in	 a	 liquid	 state.	 The	 endothelium	 regulates	 constriction	 and	dilatation	 of	 the	 vessel,	 proliferation,	 and	 migration	 of	 SMCs,	 and	 platelet	adhesion	 and	 aggregation.	 It	 controls	 thrombogenesis	 and	 fibrinolysis	 via	endogenous	autacoids,	nitric	oxide,	 and	 lipid	mediators,	 such	as	prostacyclin.11	Additionally,	 it	 acts	 as	 a	 semipermeable	 barrier	 that	 controls	 the	 exchange	 of	ions	 and	 macromolecules	 between	 blood	 and	 surrounding	 tissues	 via	 tight	
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junctions.12	The	endothelium	also	triggers	the	recruitment	and	extravasation	of	leukocytes,	for	example	after	tissue	damage,	via	expression	of	cytokines	and	cell	adhesion	molecules.13,14			
Endothelial	Dysfunction	Endothelial	 dysfunction	 is	 an	 early	 hallmark	 of	 atherogenesis	 and	 can	 predict	outcome	in	CVD.15-17	However,	it	is	now	known	that	endothelial	dysfunction	can	also	be	a	result	of	thrombosis	and	it	is	still	under	debate,	whether	it	is	a	true	risk	factor	or	rather	a	surrogate	end	point.18,19	An	important	measure	of	endothelial	function	 is	 its	 ability	 to	 trigger	 dilatation	 of	 vessels	 upon	 stimulation	 with	acetylcholine	 (ACh).20	 The	 normal	 reaction	 of	 the	 endothelium	 in	 response	 to	ACh	 is	 to	 release	nitric	oxide	 (NO),	which	 causes	 relaxation	of	 the	SMCs	of	 the	tunica	media.21	In	a	dysfunctional	endothelium,	the	ability	to	relax	the	vessel	 is	impaired.	 This	 observation	 was	 first	 made	 in	 hypertensive	 rats	 and	hypercholesterolemic	rabbits	and	very	soon	thereafter	in	human	atherosclerotic	coronary	arteries.22-24		While	 the	 endothelium	 can	 be	 stressed	 by	 many	 different	 factors,	 such	 as	hypertension,	 atherosclerosis,	 hypercholesterolemia,	 diabetes,	 and	 obesity,	 all	these	 stimuli	 may	 trigger	 endothelial	 dysfunction	 by	 an	 increase	 in	 reactive	oxygen	 species	 (ROS).25,26	 ROS	 can	 be	 free	 radicals	 that	 possess	 unpaired	electrons,	like	superoxide	(O2-)	or	NO,	or	they	can	be	compounds	with	oxidising	effects,	such	as	hydrogen	peroxide	(H2O2).27	ROS	are	constantly	produced	in	all	cell	 types,	 mainly	 by	 mitochondrial	 proteins,	 xanthine	 oxidase,	 NADH/NADPH	oxidase,	 and	 nitric	 oxide	 synthase	 (NOS).27,28	 In	 physiological	 conditions,	 ROS	play	important	roles	in	various	cell	signalling	processes	and	redox	control.26	The	presence	 of	 O2-	 is	 regulated	 via	 a	 group	 of	 antioxidant	 enzymes	 called	 the	superoxide	 dismutases,	 which	 catalyse	 the	 conversion	 of	 O2-	 into	 oxygen	 and	H2O2.	 H2O2	 is	 subsequently	 converted	 to	 water	 by	 catalase	 or	 glutathione	peroxidase.29,30	 However,	 when	 the	 generation	 of	 ROS	 in	 the	 endothelium	 is	increased	 by	 external	 stressors	 or	 can	 not	 be	 detoxified,	 these	 highly	 reactive	compounds	readily	inflict	oxidative	damage	on	DNA,	RNA,	proteins,	and	lipids.31		In	the	endothelium,	vasodilatation	can	be	 impaired	by	O2-,	which	decreases	the	bioavailability	 of	 NO	 by	 reducing	 it	 to	 peroxynitrite	 (ONOO-),	 and	 inhibits	guanylyl	 cyclase,	 a	 direct	 target	 of	 NO.32	 ONOO-	 furthermore	 also	 inhibits	guanylyl	 cyclase,	 inactivates	 endothelial	 NOS	 (eNOS),	 increases	 levels	 of	superoxide	 by	 inhibiting	 SOD,	 and	 promotes	 endothelial	 dysfunction	 by	inhibiting	prostacyclin	synthase.32	Of	note,	ROS	also	play	a	role	in	atherosclerosis	
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and	 thrombosis,	 for	 example	 via	 oxidising	 low-density	 lipoprotein	 (LDL)	 to	oxidised	 LDL	 (oxLDL),	 as	 will	 be	 discussed	 in	 the	 following	 sections.	 In	endothelial	cells,	the	presence	of	oxLDL	impairs	NO	production.33		
4.3 Atherosclerosis	Atherosclerosis	is	a	progressive	disease	that	is	characterised	by	a	chronic	vessel	inflammation	as	well	as	accumulation	of	lipids	and	fibrous	elements	in	large	arteries.34	
Initiation	of	atherosclerosis	The	 initiation	 of	 atherosclerosis	 is	 mediated	 by	 the	 endothelium,	 which	 is	activated	by	 risk	 factors	 as	described	above.	Endothelial	dysfunction	 results	 in	leaky	 tight	 junctions	 that	 permit	 circulating	 apolipoprotein	 B-containing	lipoproteins,	especially	LDL,	to	enter	the	subendothelial	space	in	the	vessel	wall	and	promote	intimal	thickening.35,36	Furthermore,	LDL	can	be	oxidised	by	ROS	to	form	 oxLDL.	 oxLDL	 induces	 endothelial	 expression	 of	 pro-atherothrombotic	genes	such	as	intercellular	adhesion	molecule	1	(ICAM-1),	vascular	cell	adhesion	molecule	 1	 (VCAM-1),	 Cyclooxygenase	 2	 (COX-2),	 and	 tissue	 factor	 (TF)	 and	activates	 SMCs	 and	 macrophages.37	 While	 the	 endothelium	 would	 resist	 firm	adhesion	with	leukocytes	in	healthy	conditions,	in	a	dysfunctional	endothelium,	ROS,	 inflammatory	 signals,	 and	 oxLDL	 trigger	 an	 increase	 in	 cellular	 adhesion	molecules,	 which	 recruit	 leukocytes,	 especially	 monocytes	 and	 T	 lymphocytes	(T-cells),	to	the	endothelium.38	Although	VCAM-1	is	most	likely	the	predominant	adhesion	 molecule	 (Figure	 3A),	 triggering	 this	 effect	 due	 to	 its	 selectivity	 for	monocytes	and	T-cells	and	its	 increased	presence	in	endothelial	cells	at	sites	of	early	atheroma,	also	ICAM-1,	P-selectin,	and	E-selectin	play	important	roles.39,40			
Leukocyte	infiltration	Once	 leukocytes	 are	 bound	 to	 the	 endothelium,	 they	 enter	 the	 intima	 by	diapedesis.40	Initially,	chemoattraction	of	leukocytes	to	the	intima	may	be	caused	by	oxLDL,	which	triggers	apoptosis	of	SMCs	via	formation	of	ROS,	which	in	turn	signals	 phagocytic	 cells	 to	 clear	 the	 cell	 debris.41,42	 This	 depends	 mostly	 on	monocyte	chemoattractant	protein-1	(MCP-1)	and	CXC	chemokines,	such	as	 IP-10,	Mig,	 and	 I-TAC,	 that	 are	 expressed	 by	 atheroma-associated	 cells,	 including	the	endothelium,	SMCs	and	macrophages	(Figure	3).43-45			Monocytes	play	a	predominant	role	in	the	atherosclerotic	lesion.	Once	inside	the	thickened	 intima,	 they	 develop	 characteristics	 of	 macrophages	 and	 start	
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endocytosis	 of	 not	 only	 dead	 cells,	 but	 also	 LDL	 and	 oxLDL.	 The	 uptake	 of	lipoproteins	 is	 mediated	 by	 an	 increase	 in	 scavenger	 receptors,	 which	mainly	results	from	macrophage	colony-stimulating	factor	(M-CSF)	overexpression	that	increases	 cytokine	 and	 growth	 factor	 production	 in	 macrophages.34,46	 The	accumulation	 of	 lipid	 droplets	 in	 their	 cytoplasm	 eventually	 transforms	macrophages	 into	 foam	cells.47	These	 cells	 produce	ROS	and	pro-inflammatory	cytokines	 that	 amplify	 the	 inflammatory	 response	 in	 the	 plaque,	 matrix	metalloproteinases	(MMPs)	that	are	able	to	destabilise	the	plaque	by	degrading	extracellular	matrix,	and	TF	that	triggers	thrombotic	complications	upon	plaque	rupture	(Figure	3A).48-51	
Figure	 3.	 Leukocyte	 infiltration	 of	 the	 vascular	 intima	 and	 its	 effects	 in	 atherosclerosis.	Adhesion	molecules	 such	 as	 vascular	 cellular	 adhesion	molecule	 1	 (VCAM-1)	 expressed	by	 the	activated	 endothelium	 facilitate	 leukocyte	 adhesion.	 A:	 Monocytes	 migrate	 into	 the	 intima	following	a	gradient	of	monocyte	chemoattractant	protein	1	(MCP-1)	that	interacts	with	their	C-C	chemokine	 receptor	 type	 2	 (CCR2).	 Then,	 monocytes	 turn	 into	 macrophages	 that	 express	scavenger	 receptors	 to	 ingest	 modified	 lipoprotein	 particles,	 such	 as	 oxLDL.	 Mediated	 by	macrophage	 colony-stimulating	 factor	 (M-CSF)	 macrophages	 accumulate	 lipid	 droplets	 which	give	 them	 characteristics	 of	 a	 foam	 cell,	 that	 is	 releasing	 ROS,	 expressing	 TF,	 matrix	metalloproteinases	(MMPs)	and	cytokines,	and	eventually	undergoes	apoptosis.		
B:	 T	 lymphocytes	 are	 migrating	 into	 the	 intima	 following	 interactions	 of	 their	 C-X-C	 motif	chemokine	 receptor	 3	 (CXCR3)	 with	 interferon-gamma	 (IFN-γ)	 inducible	 protein	 10	 (IP-10),	monokine	 induced	 by	 gamma	 interferon	 (Mig),	 and	 interferon-inducible	 T-cell	 alpha	chemoattractant	(I-TAC).	Antigens,	such	as	oxLDL,	cause	the	T-cells	to	activate	macrophages	and	to	differentiate	into	T	helper	cells	(Th1	or	Th2),	that	produce	interleukins	1	(IL-1),	4	and	10,	IFN-
γ and	tumour	necrosis	factor	(TNF).	Adapted	from	Libby,	Nature,	2002.34	
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oxLDL	not	only	affects	macrophages	but	also	stimulates	plaque	resident	T-cells	along	with	other	antigens.	These	T-cells	can	then	activate	macrophages	directly	via	 CD40-CD154	 interaction,	 or	 differentiate	 into	 T	 helper	 (Th)	 1	 or	 2	 cells,	which	 further	 amplify	 the	 inflammation	 in	 the	 lesion	 by	 releasing	 cytokines	(Figure	3B).52-54		
Plaque	progression	and	rupture	Stimulated	by	lipids	and	lipoproteins,	macrophages	and	SMCs	accumulate	in	the	subendothelial	 layer	 of	 the	 arterial	 wall.	 Subsequently,	 they	 may	 undergo	apoptosis	 or	 necrosis	 and	 form	 the	 necrotic	 core,	 which	 further	 enhances	inflammation	 and	 recruitment	 of	 additional	 leukocytes.55-58	 These	 processes	establish	 a	 vicious	 cycle	 that	 promotes	 progression	 and	 growth	 of	 an	atherosclerotic	lesion	(Figure	4).		In	 an	 advanced	 atherosclerotic	 lesion,	 SMCs	migrate	 to	 the	 intima	where	 they	form	a	collagen-rich	fibrous	cap	that	separates	the	atherosclerotic	core	from	the	vessel	 lumen	and	stabilises	the	plaque.	This	cap	can	rupture	mediated	by	SMC-apoptosis	and	destabilising	factors,	such	as	MMPs,	which	subsequently	exposes	highly	 thrombogenic	 core	 material	 to	 the	 blood,	 causing	 thrombosis	 (Figure	
4).59,60		
Figure	4.	Development	 of	 endothelial	 dysfunction	 and	progression	 to	 atherothrombosis.	Excess	 reactive	 oxygen	 species	 (ROS)	 oxidise	 low-density	 lipoprotein	 (LDL)	 to	 oxLDL	 which	transmigrates	 in	 the	 tunica	 intima,	 leading	 to	 endothelial	 activation.	 Circulating	 monocytes	adhere	 to	 the	 activated	 endothelium,	 transmigrate	 into	 the	 subendothelial	 space	 and	differentiate	 into	macrophages.	ROS,	 generated	 from	endothelial	 cells,	 vascular	 smooth	muscle	cells	 (VSMCs)	 and	 macrophages	 further	 promote	 the	 oxidization	 of	 LDL	 particles,	 which	 are	taken	up	by	macrophages	that	in	turn	differentiate	into	foam	cells	(FC).	Accumulating	foam	cells	form	fatty	streaks.	VSMCs	migrate	into	the	arterial	intima	forming	a	fibrous	cap,	which	covers	the	lipid-rich	 core	 of	 the	 progressing	 atheroma.	 Apoptosis	 of	 plaque-resident	 cells	 contributes	 to	fibrous	 cap	 thinning	 and	 eventual	 plaque	 rupture.	 Figure	 created	 by	 Dr.	 Stephan	 Winnik,	
University	Hospital	Zurich.		
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4.4 Arterial	thrombosis	Blood	coagulation	is	a	central	mechanism	in	wound	repair	that	is	indispensable	to	seal	a	damaged	vessel,	prevent	blood	 loss,	and	 initiate	the	healing	process.61	However,	 in	 occurrence	 of	 atherosclerosis,	 coagulation	 can	 be	 triggered	pathologically	by	rupture	of	an	atherosclerotic	plaque	or	plaque	erosion,	which	is	 characterised	 by	 an	 absence	 of	 the	 endothelium.62,63	 In	 these	 cases,	coagulation	 may	 lead	 to	 thrombosis	 of	 an	 artery.	 Arterial	 thrombosis	 is	 the	occlusion	of	 an	 artery	by	 a	blood	 clot	 and	hence	 an	obstruction	of	 oxygen	and	nutrient	flow	to	the	adjacent	tissues.	It	is	the	major	complication	in	CVD	and	may	lead	to	stroke	or	myocardial	infarction.64			
Tissue	factor	and	the	coagulation	cascade	The	coagulation	cascade	consists	of	 a	number	of	 inactive	 soluble	 factors	 in	 the	blood	 that	 subsequently	 activate	 each	 other	 to	 generate	 clot	 stabilising	 fibrin	molecules	and	thrombin,	which	initiates	platelet	aggregation.	A	central	activator	of	the	coagulation	cascade	is	tissue	factor	(TF).	TF	is	a	protein	of	47	kDa	that	is	constitutively	expressed	 in	cells	of	 the	adventitia	and	SMCs	of	 the	media,	while	its	expression	is	latent	but	can	be	induced	in	leukocytes	and	the	endothelium.65-67	Originally,	the	endothelium	was	thought	to	be	a	natural	barrier	separating	TF	in	the	inner	vascular	wall	from	the	other	coagulation	factors	in	the	blood	stream,	but	 it	 is	 now	 known	 that	 TF	 also	 exists	 in	 the	 blood	 in	 form	 of	 latent	 TF	microparticles	and	as	an	alternatively	spliced	soluble	form.68-71			Once	active	TF	gets	in	contact	with	blood	it	binds	to	coagulation	factor	VII	(FVII),	which	is	subsequently	activated	to	FVIIa.	The	interaction	of	TF	and	FVII	initiates	the	extrinsic	coagulation	cascade	(Figure	5).	The	TF:FVIIa	complex	activates	FX	and	FIX.	FIXa	initiates	the	intrinsic	coagulation	cascade,	which	further	amplifies	this	process	by	forming	a	complex	with	FVIIIa	that	also	activates	FX.	FXa	binds	to	FVa	and	 the	FXa:FVa	 complex	 cleaves	prothrombin	 to	 thrombin,	which	plays	a	central	 role	 in	 the	 coagulation	 cascade.72	 Thrombin	 activates	 platelets	 by	cleaving	 protease-activated	 receptors,	 cleaves	 fibrinogen	 to	 soluble	 fibrin	monomers,	and	activates	FXIII,	which	links	these	monomers	to	a	clot-stabilising	fibrin	 polymer	 (Figure	 5).73,74	 Furthermore,	 thrombin	 enhances	 the	 intrinsic	pathway	 by	 activating	 FXI,	 which	 in	 turn	 activates	 FIX.75,76	 More	 recently,	coagulation	factor	FXII,	that	had	been	thought	to	have	no	function	in	coagulation	
in	vivo,	has	been	identified	as	an	important	initiator	of	the	intrinsic	pathway,	as	it	is	able	to	activate	FXI.77	
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Figure	 5.	 The	 coagulation	 cascade.	 Formation	 of	 the	 TF:FVIIa	 complex	 initiates	 clotting	 by	activating	FX	and	FIX.	Alternatively,	FXI	can	activate	FIX.	The	prothrombinase	complex	(FVa:FXa)	activates	 prothrombin	 (PT).	 Thrombin	 activates	 various	 proteases	 and	 cofactors.	 Thrombin	cleaves	 fibrinogen	 (Fbg)	 to	 soluble	 monomers	 (SFM),	 which	 are	 cross-linked	 by	 FXIIIa,	 and	activates	protease-activated	receptors	(PARs)	on	platelets,	which	leads	to	the	formation	of	a	clot.	
From	Mackman	et	al.,	ATVB,	2007.72		To	 keep	 homeostasis	 in	 physiological	 conditions,	 the	 coagulation	 cascade	 is	regulated	by	a	number	of	 inhibitors.	Among	 the	most	 important	 regulators	are	TF	 pathway	 inhibitor	 (TFPI)	 which	 inhibits	 the	 TF:FVIIa	 complex	 and	 FXa;	Protein	 C	 which	 is	 inhibiting	 FVa	 and	 FVIIIa;	 and	 antithrombin	 which	 is	inhibiting	thrombin,	FXa,	FIXa	and	FVIIa.78-80		
Platelets	Platelets	are	fragments	of	megakaryocytes	without	a	nucleus	that	are	shed	in	the	process	of	megakaryocyte	maturation	either	in	bone	marrow	or	the	lung.81	The	life	 cycle	 of	 a	 platelet	 is	 limited	 to	 5-7	 days	 during	which	 it	 decreases	 in	 size.	After	 this	 time,	or	after	activation	and	 incorporation	 into	a	blood	clot,	platelets	are	 cleared	 by	 neutrophils	 and	macrophages	 and	 disposed	 of	 via	 the	 spleen.82	Platelets	possess	a	characteristic	receptor-rich	cell	membrane	and	granules	that	contain	adhesion	molecules	and	platelet	agonists.		In	 healthy	 conditions,	 the	 endothelium	 and	 platelets	 do	 not	 favour	 adhesion.	Both	 cell	 types	 are	 negatively	 charged	 and	 the	 endothelium	 produces	prostacyclin	and	NO,	which	raise	cyclic	adenosine	monophosphate	 (cAMP)	and	
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cyclic	guanosine	monophosphate	(cGMP)	levels	in	platelets.83,84	cAMP	and	cGMP	stimulate	 protein	 kinases	 A	 and	 C	 to	 phosphorylate	 platelet	 agonist	 receptors,	which	keeps	platelets	inactivated.		However,	 the	 subendothelial	matrix	 contains	many	proteins,	which	 are	 able	 to	activate	platelets	and	facilitate	binding.	Upon	vascular	injury,	such	as	the	rupture	of	an	atherosclerotic	plaque,	the	subendothelial	matrix	is	exposed	to	platelets	in	the	 blood.	 Platelet	 binding	 to	 the	 vascular	 wall	 is	 then	 facilitated	 most	prominently	by	glycoprotein	and	 integrin	receptor	binding	 to	collagen	and	von	Willebrand	factor	(vWF).82	Firm	adhesion,	which	leads	to	a	flattened	shape	of	the	platelets,	 is	 additionally	 catalysed	 by	 atherosclerosis	 associated	 endothelial	dysfunction,	which	 limits	 the	availability	of	 the	physiological	platelet	 inhibitors	prostacyclins	and	NO.85	Secondary	to	firm	adhesion	of	platelets	is	their	activation	by	agonists,	such	as	collagen,	ADP,	Thromboxane	A2,	and	the	most	potent	platelet	activator	thrombin	(Figure	6).86		
Figure	 6.	 Role	 of	 platelets	 in	 haemostasis	 and	 thrombosis.	 Upon	 endothelial	 activation	 or	damage,	 platelets	 are	 able	 to	 bind	 to	 the	 endothelium	 or	 the	 subendothelial	 matrix.	 This	increasingly	 takes	place	upon	vascular	 injury,	where	matrix-derived	proteins,	 such	as	 collagen,	are	 exposed	 to	 the	 blood.	 Once	 a	 platelet	 gets	 activated,	 its	 shape	 shifts	 and	 it	 recruits	 more	platelets	 that	 begin	 to	 aggregate	 and	 form	 a	 thrombus.	 RBC:	 Red	 blood	 cell.	 Adapted	 from	
Holinstat	et	al.,	Cancer	Metastasis	Rev,	2017.82		Activated	 platelets	 undergo	 key	 structural	 changes	 induced	 by	 an	 agonist-mediated	 increase	 in	 calcium	 levels,	 and	 increase	 their	 surface	 area	approximately	by	4-fold.	Additionally,	activated	platelets	externalise	all	contents	of	their	granules,	which	are	laden	with	platelet	adhesion	molecules,	such	as	vWF,	p-selectin,	 and	 fibrinogen,	 as	 well	 as	 platelet	 agonists,	 mostly	 ADP.	 These	proteins	 recruit	more	 platelets	 and	 cause	 them	 to	 aggregate.	 The	 platelets	 are	further	 linked	 to	 each	 other	 and	 stabilised	 by	 fibrinogen	 and	 fibrin	molecules	from	 the	 coagulation	 cascade.87	 Finally,	 activated	 platelets	 also	 provide	 an	effective	catalytic	surface	for	the	activation	of	the	coagulation	cascade.88	
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4.5 Neutrophils	in	Atherothrombosis	
This	chapter	is	based	on:		
Gaul	DS,	Stein	S,	Matter	CM.	Neutrophils	in	cardiovascular	disease.	
Eur	Heart	J	2017;	38(22):	1702-4	
	As	 leukocytes	 are	 involved	 in	 inflammatory	 responses	 of	 the	 body,	 it	 is	 no	surprise	 that	 they	 are	 also	 involved	 in	 chronic	 inflammatory	 diseases,	 like	atherosclerosis.	 In	 the	 past,	many	 atherothrombosis	 studies	 focused	 especially	on	 the	 role	 of	 monocyte/macrophages	 and	 T-cells.	 However,	 more	 recently,	neutrophils	have	gained	a	lot	of	interest	and	emerged	as	intriguing	new	players	in	atherothrombosis.89		
Normal	neutrophil	function	Neutrophils	 are	 polymorphonuclear	 leukocytes	 that	 form	 the	 initial	 defence	against	 pathogens	 and	 protect	 the	 host	 by	mediating	 inflammatory	 and	 innate	immune	 responses.90	 Neutrophils	 have	 developed	 distinct	 mechanisms	 to	 be	able	 to	 defend	 their	 host:	 phagocytosis,	 apoptosis,	 externalisation	 of	 anti-pathogenic	 granule	 content,	 release	 of	 ROS,	 and	 formation	 of	 neutrophil	extracellular	traps	(NETs).91	These	powerful	immune	responses	can	be	triggered	by	 pathogens,	 such	 as	 bacterial	 lipopolysaccharide	 (LPS),	 cytokines,	 and	 other	inflammatory	 cells	 or	 stimuli.	 However,	 they	 can	 be	 detrimental	 in	 a	 disease	context.	
Neutrophils	in	atherosclerosis	Neutrophils	 are	 recruited	 to	 an	 atherosclerotic	 lesion	 by	 macrophage-derived	chemokines	and	transmigrate	into	the	lesion	via	oxLDL-dependent	upregulation	of	ICAM-1	and	increased	contractility	of	endothelial	cells.92-94		Once	 inside	a	 lesion,	 the	neutrophils	start	to	react	to	the	ongoing	inflammation	with	 the	 intention	 to	 resolve	 it,	 but	 eventually	 they	 worsen	 the	 outcome.	Degranulated	 proteins	 recruit	 more	 monocytes	 by	 facilitating	 adhesion	 to	 the	endothelium,	 promote	 plaque	 instability	 by	 breaking	 down	 collagen,	 and	catalyse	 lipoprotein	 oxidation.95-99	 The	 same	 effects	 are	 caused	 by	 release	 of	ROS.100	Finally,	neutrophils	in	the	atheroma	readily	undergo	apoptosis	and	thus	release	 signals	 that	 yet	 again	 recruit	 monocyte/macrophages	 into	 the	 plaque	(Figure	7).101,102		
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Neutrophils	in	thrombosis	and	ischaemia-reperfusion	injury	In	 endothelial	 damage-mediated	 thrombosis,	 neutrophils	 have	 been	 shown	 to	initiate	thrombus	formation	by	being	the	first	cell-type	physically	present	at	the	site	of	damage	and	providing	TF	to	trigger	coagulation.67	The	neutrophil-derived	proteinases	 cathepsin	 G	 and	 elastase	 furthermore	 degrade	 TFPI,	 the	 main	inhibitor	 of	 the	 extrinsic	 coagulation	 pathway.103	 Finally,	 ROS	 released	 by	neutrophils	at	the	site	of	thrombus	formation	can	activate	platelets	(Figure	7).104		Neutrophils	 do	 not	 only	 aggravate	 thrombotic	 processes,	 they	 also	 play	 an	important	 role	 in	 the	 processes	 following	 the	 dissolution	 of	 a	 thrombotic	occlusion.	 If	 a	 coronary	 artery	 is	 occluded,	 a	 quick	 reperfusion	 is	 essential	 to	save	the	myocardial	tissue	from	ischaemia.105	After	reperfusion,	neutrophils	are	recruited	to	the	infarcted	tissue	by	dying	cells	and	damaged	extracellular	matrix,	where	 they	 clear	 dead	 cells	 and	 recruit	monocytes	 that	 degrade	 the	 damaged	matrix.106	 While	 this	 is	 initially	 beneficial,	 secondary	 effects	 by	 activated	neutrophils,	 such	 as	 degranulation	 and	 ROS	 release,	 damage	 intact	 cells	 and	extracellular	matrix,	which	may	 increase	 infarct	 size.	 Indeed,	 reperfusion	with	neutrophil-deprived	 blood	 reduced	 injury	 in	 dogs	 and	 reperfusion	 injury	 is	associated	with	recurrent	atherosclerosis	in	mice	and	patients.107-109			
Neutrophil	extracellular	traps	and	cardiovascular	disease	NETs	have	only	recently	gotten	into	focus	of	research,	but	already	now	it	is	clear	that	 NET	 formation	 occurs	 in	 a	 remarkable	 number	 of	 diseases	 where	neutrophils	 are	 involved,	 indicating	 that	 its	 importance	 may	 have	 been	overlooked	in	the	past.89			NETs	 consist	 of	 externalised	 neutrophil	 DNA	 and	 granular	 proteins,	 which	enable	 them	 to	 kill	 pathogens.110	 They	 can	 be	 triggered	 by	 pathogen-derived	endotoxins,	 like	 LPS,	 or	 by	 P-selectin	 expressed	 in	 activated	 platelets	 and	endothelial	cells.111,112		There	 are	 currently	 two	 models	 of	 NETs	 discussed:	 NETs	 containing	 nuclear	DNA	 that	 are	 released	 during	 a	 programmed	 cell	 death,	 and	 NETs	 containing	mitochondrial	DNA	that	can	be	released	by	viable	neutrophils.113,114	While	both	mechanisms	 of	 NET	 formation	 may	 exist,	 both	 hypotheses	 agree	 that	 the	formation	of	NETs	depends	on	the	generation	of	ROS.115,116			NETs	have	been	identified	in	human	atherosclerotic	lesions,	where	they	promote	atherogenesis	 and	 are	 associated	 with	 a	 severe	 atherothrombotic	 state,	 likely	
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due	 to	 release	 of	 granular	 proteins,	 ROS	 and	 pro-thrombotic	 factors	 (Figure	
7).117,118	 Furthermore,	 NETs	 can	 be	 induced	 by	 the	 activated	 endothelium	 and	are	susceptible	to	NET-mediated	cell	death.112		
Figure	7.	Effects	of	neutrophils	in	atherosclerosis,	thrombosis,	and	ischaemia-reperfusion	
injury.	NETs:	neutrophil	extracellular	traps;	ROS:	reactive	oxygen	species;	oxLDL:	oxidised	low-density	lipoprotein.	From	Gaul	et	al.,	Eur	Heart	J,	2017.89		NETs	demonstrate	strong	pro-thrombotic	properties.	Indeed,	the	use	of	DNAse	I	to	 degrade	 NETs	 in	 animals	 reduced	 thrombosis,	 myocardial	 infarction,	 and	ischemic	stroke.119-122	Importantly,	NETs	also	occur	in	human	coronary	thrombi,	where	 they	 are	 associated	 with	 coronary	 infarct	 size.123-125	 When	 neutrophils	release	 DNA,	 this	 huge	 molecule	 acts	 as	 a	 surface	 that	 binds	 TF,	 FXII,	 and	granular	proteins,	like	TFPI	inhibitors	cathepsin	G	or	elastase,	and	thus	activates	both	 the	 extrinsic	 as	 well	 as	 the	 intrinsic	 coagulation	 pathway.103,126,127	Furthermore,	 NETs	 bind	 vWF,	 fibronectin,	 and	 fibrinogen,	 all	 of	 which	 are	triggering	platelet	binding	and	aggregation.112,128		Finally,	 NETs	 are	 also	 implicated	 in	 ischaemia-reperfusion	 injury	 in	 rats	 and	degradation	 of	 NETs	 is	 discussed	 to	 be	 therapeutically	 used	 to	 decrease	 the	severity	of	this	injury	(Figure	7).129		
4.6 Sirtuins	-	mediators	of	caloric	restriction	Silent	information	regulator	2	proteins	(sirtuins)	are	a	protein	family	consisting	of	seven	members	(Sirt1-7)	that	are	highly	conserved	between	species	and	occur	in	 different	 cellular	 compartments	 (Figure	 8A).130	 All	 sirtuins	 exhibit	 protein	
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deacetylase	 activity,	 but	 some	 of	 the	 members	 also	 act	 as	 ADP-ribosylases	and/or	 deacylases	 of	 succinyl,	 malonyl,	 glutaryl	 or	 long-chain	 fatty	 acyl	groups.131	 Regardless	 of	 their	 functions,	 all	 sirtuins	 are	 dependent	 on	 the	cofactor	 NAD+	 and,	 consequently,	 sirtuin	 activity	 is	 increased	 in	 times	 of	 low	nutrient	 availability	 (Figure	 8B).132	 Interestingly,	 caloric	 restriction	 has	 been	shown	 to	 prolong	 life	 span	 and	 delay	 onset	 of	 age-related	 diseases	 in	 many	species,	including	mammals.133-135	When	first	studies	in	yeast	showed	that	many	of	these	effects	may	be	mediated	by	the	sirtuins	in	1999,	many	researchers	took	an	 interest	 in	 deciphering	 the	 underlying	 molecular	 mechanisms.136	 It	 is	 now	known	that	sirtuins	possess	many	beneficial	roles	in	survival	and	aging	(Figure	
8B),	 and	 some	 of	 them	 have	 been	 associated	 with	 longevity	 in	 mice	 and	humans.137,138	 To	 date,	 the	 only	 efficient	 way	 to	 activate	 sirtuins	 is	 by	 caloric	restriction.139		
Figure	8.	 The	 sirtuin	 family	 of	 protein	deacetylases.	A:	The	sirtuin	 family	consists	of	seven	members	 that	 are	 distributed	 in	 different	 cell	 compartments.	 While	 Sirt2	 is	 found	 in	 the	cytoplasm,	 Sirt1	 can	be	both	 located	 in	 cytoplasm	and	 the	nucleus.	 Sirt6	 and	Sirt7	 are	nuclear	proteins	 and	 Sirt3-5	 are	 located	 in	 the	 mitochondria.	 B:	 Sirtuins	 are	 NAD+-dependent	deacetylases	 that	 target	 histone	 and	 nonhistone	 proteins	 (left	 upper	 box)	 to	 regulate	 a	 wide	range	of	cellular	functions	such	as	cellular	senescence,	survival,	DNA	repair,	metabolism,	and	cell	cycle	 progression.	 Because	 sirtuins	 require	 NAD+	 for	 their	 catalytic	 activity,	 their	 enzymatic	activity	is	higher	in	situations	of	energy	distress.	Figure	8A	was	retrieved	from	the	Denu	Lab	at	the	
University	 of	 Wisconsin-Madison	 (http://devriesgen677s09.weebly.com/sirtuin-family.html)	 and	
Figure	8B	was	adapted	from	Oellerich	et	al.,	Circ	Res,	2012.140		
Sirtuins	in	cardiovascular	disease	Sirtuins	 take	 over	 particularly	 interesting	 roles	 in	 CVD,	 as	 they	 are	 positively	influencing	 a	 number	 of	 cardiovascular	 risk	 factors,	 such	 as	 the	 metabolic	syndrome.141,142	 Metabolic	 syndrome	 is	 triggered	 by	 high-caloric	 diets	 and	physical	 inactivity	 and	 is	 characterised	 by	 the	 combination	 of	 high	 blood	pressure,	 obesity,	 inflammation,	 glucose	 intolerance,	 and	 dyslipidaemia,	 all	 of	which	are	associated	with	development	of	CVD	and	diabetes.143	Sirt1,	 the	best-
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characterised	member	 of	 the	 sirtuins,	 for	 instance,	 is	 able	 to	 improve	 glucose	tolerance	 and	 lipid	 homeostasis	 and	 thus	 confers	 atheroprotection.144-146	However,	 sirtuins	 are	 also	 directly	 involved	 in	 endothelial	 function,	atherosclerosis,	 and	 thrombosis.141	 This	 dissertation	 is	 focusing	 on	 the	 role	 of	Sirtuin	3	and	Sirtuin	6	in	CVD.	
Sirtuin	3	in	cardiovascular	disease	Sirtuin	 3	 (Sirt3)	 is	 a	 mitochondrial	 deacetylase,	 which	 affects	 acetylation	 of	hundreds	 of	 mitochondrial	 proteins	 and	 thereby	 maintains	 mitochondrial	function	and	homeostasis.131,147-149			In	 times	 of	 low	 energy,	 NAD+	 levels	 rise	 and	 activate	 Sirt3,	 which	 in	 turn	deacetylates	 and	 thus	 activates	 long-chain	 acyl	 CoA	 dehydrogenase	 (LCAD),	acetyl	coenzyme	A-synthetase	2	(AceCS2),	glutamate	dehydrogenase	(GDH),	and	isocitrate	dehydrogenase	2	(IDH2)	(Figure	9).150-152	LCAD	and	AceCS2	generate	acetyl	 coenzyme	 A	 (Acetyl-CoA)	 via	 oxidation	 of	 fatty	 acids	 and	 conversion	 of	acetate,	 respectively.150,151	 GDH	 and	 IDH2	 are	 involved	 in	 the	 generation	 of	α-ketoglutarate.152-154	 Both	 acetyl-CoA	 and	 α-ketoglutarate	 are	 important	substrates	in	the	tricarboxylic	acid	(TCA)	cycle	and	hence	activate	it,	which	leads	to	 improved	 regeneration	 of	 NADH	 from	 NAD+.	 NADH	 is	 needed	 to	 fuel	 the	oxidative	 phosphorylation	 cascade	 to	 generate	 energy	 in	 form	 of	 adenosine	triphosphate	(ATP).		Sirt3	is	not	only	indirectly	providing	NADH	for	the	oxidative	phosphorylation,	it	is	also	able	to	activate	complex	I,	III	and	V	of	this	cascade	directly,	and	complex	II	via	deacetylation	of	succinate	dehydrogenase	(SDH)	(Figure	9).155-158	Again	this	leads	 to	 an	 increased	 generation	 of	 ATP	 and	 the	 cell	 can	 keep	 up	 energy	production	in	absence	of	nutrients	with	these	mechanisms.		During	 the	synthesis	of	ATP	 in	 the	oxidative	phosphorylation	cascade,	ROS	are	generated	as	by-products.159	In	fact,	mitochondria	are	a	major	source	of	cellular	ROS,	 as	 approximately	 1-2%	 of	 all	 oxygen	 that	 is	 consumed	 by	 oxidative	phosphorylation	 is	converted	 to	superoxide	(O2-)	due	 to	 leakage.160	Superoxide	dismutase	 2	 (SOD2)	 is	 the	 main	 scavenger	 of	 O2-	 in	 mitochondria.	 It	 directly	converts	 O2-	 to	 hydrogen	 peroxide	 (H2O2),	 which	 is	 furthermore	 converted	 to	water	 by	 catalase	 (CAT)	 or	 glutathione	 peroxidase.29,30	 Sirt3	 stimulates	 this	process	by	activating	transcription	factor	Foxo3a,	which	upregulates	expression	of	 SOD2	 and	 CAT	 (Figure	 9).161	Moreover,	 Sirt3	 deacetylates	 SOD2	 directly	 at	
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lysine	(K)	58,	89	and	122,	which	are	adjacent	to	the	active	site	of	SOD2,	and	thus	increases	its	enzymatic	activity	and	capacity	to	scavenge	O2-.162,163		
	
Figure	9.	The	role	of	Sirt3	in	mitochondrial	homeostasis.	Sirt3	is	maintaining	mitochondrial	homeostasis	 in	 low	energy	 conditions	on	 three	 levels:	 (1)	By	activating	enzymes	 that	 generate	substrates	 for	 the	 tricarboxylic	 acid	 (TCA)	 cycle,	 it	 is	 facilitating	 regeneration	 of	 reduced	nicotinamide	adenine	dinucleotide	(NADH);	(2)	By	direct	and	indirect	activation	of	complexes	I,	II,	III,	and	V	it	is	increasing	oxidative	phosphorylation	and	generation	of	adenosine	triphosphate	(ATP);	(3)	By	activating	superoxide	dismutase	2	(SOD2)	and	transcriptionally	upregulating	SOD2	and	Catalase	 (CAT),	 it	 is	 scavenging	 reactive	oxygen	 species	 (ROS).	GLUT:	 glucose	 transporter;	LCAD:	 long-chain	 acyl	 CoA	 dehydrogenase;	 AceCS2:	 acetyl	 coenzyme	 A-synthetase	 2;	 IDH2:	isocitrate	 dehydrogenase	 2;	 GDH:	 glutamate	 dehydrogenase;	 SDH:	 succinate	 dehydrogenase;	ADP:	 adenosine	 diphosphate;	 Pi:	 inorganic	 phosphate.	Adapted	 from	Houtkooper	et	al.,	Nat	Rev	
Mol	Cell	Biol,	2012.145		An	excess	of	ROS	in	the	mitochondria	may	induce	mitochondrial	dysfunction	and	apoptosis,	leading	to	ageing	and	age-related	diseases.28	Consequently,	deletion	of	Sirt3	in	mice	accelerates	development	of	diabetes,	metabolic	syndrome,	and	age-related	 hearing	 loss,	 and	 induces	 pulmonary	 artery	 hypertension.153,156,164,165	Interestingly,	 these	 effects	 in	 Sirt3-depleted	 mice	 are	 only	 obvious,	 if	 an	additional	 stressor,	 such	 as	 a	 chronic	 high	 fat	 diet	 is	 used	 to	 challenge	 the	system.148,164	Along	 these	 lines,	Sirt3	 is	able	 to	prevent	cardiac	hypertrophy	by	decreasing	 ROS	 levels	 via	 SOD2	 and	 CAT,	 and	 by	 regulating	 the	mitochondrial	
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permeability	 transition	 pore	 to	 prevent	 mitochondrial	 dysfunction.161,166	 Sirt3	also	 protects	 cultured	 endothelial	 cells	 from	 mitochondrial	 ROS	 and	cardiomyocytes	 from	 stress-induced	 apoptosis.167,168	 Finally,	 Sirt3	 has	 been	associated	with	longevity	in	humans.137,169		Prior	 to	 the	 work	 presented	 in	 this	 dissertation,	 the	 role	 of	 Sirt3	 in	atherosclerosis,	 endothelial	 function,	 and	 arterial	 thrombosis	 had	 not	 been	investigated.	
Sirtuin	6	in	cardiovascular	disease	Sirtuin	6	(Sirt6)	is	a	nuclear-located	sirtuin	that	acts	as	deacetylase,	deacylase	of	long-chain	 fatty	 acyl	 groups,	 and	 as	 ADP-ribosyltransferase.170	 Sirt6	 exerts	 a	wide	 range	 of	 effects	 on	 metabolism,	 inflammation,	 and	 ageing.	 Indeed,	 a	constitutive	global	deletion	of	Sirt6	in	mice	leads	to	an	aging-like	phenotype	and	severe	 hypoglycaemia,	 which	 causes	 60%	 of	 the	 animals	 to	 die	 at	 an	 age	 of	approximately	4	weeks,	and	the	rest	within	1	year.171,172	Overexpression	of	Sirt6,	on	 the	 other	 hand,	 is	 able	 to	 increase	 lifespan	 in	male	mice	 and	protects	 from	consequences	 of	 diet-induced	 obesity.173	 Of	 Sirt6’s	 molecular	 functions,	 the	deacetylation	of	lysines	of	histone	3	(H3)	are	especially	well	characterised	and	to	date,	 the	 lysines	 (K)	 9,	 18	 and	 56	 of	 H3	 have	 been	 identified	 as	 deacetylation	targets.174-176		Sirt6	mediates	glucose	homeostasis	via	H3	deacetylation-dependent	inhibition	of	expression	 of	 HIF1α-dependent	 glycolytic	 genes,	 and	 via	 direct	 acetylation	 of	general	 control	 non-repressed	 protein	 5	 (GCN5),	 which	 controls	 hepatic	gluconeogenesis.177,178	In	the	same	fashion,	Sirt6	acts	as	a	tumour	suppressor	by	inhibiting	aerobic	glycolysis	in	tumour	cells.179	Sirt6	is	furthermore	implicated	in	tumour	 suppression,	 as	 it	 represses	 NF-κB-mediated	 gene-transcription	 of	survivin-	 and	 c-MYC-mediated	 ribosomal	 biogenesis	 in	 cancer	 cells	 (Figure	
10).179,180	 Interestingly	 in	 some	 studies,	 Sirt6	 has	 been	 shown	 to	 play	 an	oncogenic	 role.181,182	 This	 is	 likely	 due	 to	 the	 function	 of	 Sirt6	 as	 a	 keeper	 of	genomic	stability.170		Sirt6	plays	an	important	role	in	the	maintenance	of	genomic	stability	by	affecting	telomere	structure	and	function	and	by	mediating	DNA	repair.	Via	deacetylation	of	H3K9	and	H3K56,	Sirt6	facilitates	the	proper	association	of	Werner	syndrome	protein	(WRN)	with	telomeric	chromatin	and	hence	regulates	adequate	capping	of	 telomeres.174,183,184	 Additionally,	 Sirt6	 is	 involved	 in	 DNA	 repair,	 especially	double-strand	 break	 (DSB)	 repair.	 It	 ADP-ribosylates	 poly	 [ADP-ribose]	
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polymerase	1	(PARP1),	a	protein	mediating	base	excision	and	DSB	repair.171,185	Furthermore,	it	protects	from	DSB	and	improves	homologous	recombination,	by	deacetylating	 C-terminal	 binding	 protein	 interacting	 protein	 (CtIP),	 stabilises	DNA-dependent	protein	kinase	at	chromatin	for	DSB	repair,	and	recruits	sucrose	nonfermenting	2	homologue	 (SNF2H)	 to	DNA-break	sites	 to	mediate	 repair.186-188	 These	 observations	 highlight	 a	 beneficial	 role	 of	 Sirt6	 in	 ageing,	 which	 is	furthermore	 supported	 by	 the	 notion	 that	 Sirt6	 can	 translocate	 into	 the	cytoplasm	in	stress	conditions	where	it	promotes	dephosphorylation	of	Ras-GAP	SH3	domain	binding	protein	(G3BP),	which	regulates	structure	and	dynamics	of	stress	granules	(Figure	10).189			
Figure	 10.	 Sirt6	 cellular	 functions	 and	 their	 impact	 on	 organismal	 biology	 and	 disease.	Sirt6	primarily	 functions	as	an	H3K9	and	H3K56	histone	deacetylase	 that	decreases	chromatin	accessibility	 for	 transcription	 factors	 such	 as	 nuclear	 factor	 kappa	 (NF-κB)	 or	 c-JUN	 to	 their	respective	promoters	and	 thus	 inhibits	expression	of	 their	 target	genes.	Sirt6	can	also	regulate	protein	activity	 through	direct	or	 indirect	deacetylation,	deacylation,	and	ADP-ribosylation.	Via	these	mechanisms,	Sirt6	 is	mediating	 stress	 response,	DNA	repair,	 glucose	metabolism,	 cancer,	telomere	maintenance,	 lipid	metabolism,	and	inflammation.	Solid	arrow:	Sirt6	directly	modifies	the	 protein	 or	 directly	 affects	 histone	 deacetylation	 at	 the	 promoters	 of	 target	 genes.	 Dashed	arrow:	 Sirt6	 deacetylation	 activity	 is	 necessary,	 but	 is	 not	 direct.	 Red	 arrows:	 Histone	deacetylation.	 P	 (phosphorylation),	 Ac	 (acetylation)	 and	 R	 (ADP-ribosylation).	 Adapted	 from	
Kugel	et	al.,	Trends	Biochem	Sci,	2014.170	
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Sirt6	 also	 has	 beneficial	 functions	 in	 preventing	 the	 development	 of	metabolic	CVD	risk	factors.	Not	only	may	it	be	a	therapeutic	target	to	improve	diabetes	due	to	 its	 involvement	 in	 glucose	metabolism,	 it	 also	 positively	 affects	 blood	 lipid	levels.190-192	 By	 deacetylation	 of	 H3K9	 and	 H3K56,	 Sirt6	 inhibits	 FoxO3-dependent	expression	of	proprotein	convertase	subtilisin/kexin	type	9	(PCSK9)	gene,	 which	 is	 promoting	 degradation	 of	 LDL-receptor,	 and	 of	 the	 sterol-regulatory	element	binding	protein	(SREBP)	gene,	a	key	regulator	of	cholesterol	biosynthesis	(Figure	10).191-193			Sirt6	 can	also	 regulate	 inflammatory	 responses	and,	depending	on	 the	 context,	acts	pro-	or	anti-inflammatory.	Acylating	a	long-chain	fatty	acyl	lysine,	Sirt6	can	catalyse	the	hydrolysis	of	lysine	K19	and	K20	of	tumour	necrosis	factor-α	(TNF-
α),	 triggering	 TNF-α	 secretion	 from	 the	 cell.194	 TNF-α	 is	 an	 important	 pro-inflammatory	 mediator	 that	 triggers	 transcription	 of	 NF-κB-	 and	 AP-1-dependent	 pro-inflammatory	 genes.	 On	 the	 other	 hand,	 Sirt6	 is	 able	 to	 inhibit	exactly	these	two	transcription	factors.	By	association	with	NF-κB	subunit	RelA	(p65)	and	AP-1	subunit	c-JUN,	Sirt6	deacetylates	H3K9	and	represses	the	activity	of	NF-κB-	and	AP-1	(Figure	10).195,196		The	 interaction	 of	 Sirt6	 and	 c-JUN	 is	 also	 thought	 to	 protect	 from	 cardiac	hypertrophy	 and	 heart	 failure.197,198	 In	 a	 mouse	 model	 of	 atherosclerosis,	deletion	 of	 one	 Sirt6-allele	 caused	 endothelial	 dysfunction	 and	 increased	atherosclerosis.199	 In	 vitro	 studies	 suggest,	 that	 these	 effects	 are	 triggered	 by	increased	 expression	 of	 VCAM-1	 and	 induction	 of	 pro-inflammatory	 cytokines	via	NF-κB	in	endothelial	cells.199,200		However,	the	role	of	Sirt6	in	arterial	thrombosis	remains	elusive.		 	
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5 Hypotheses	and	research	aims	Having	 in	mind	the	roles	of	Sirt3	and	Sirt6	 in	metabolic	syndrome,	ageing,	and	stress,	 we	 hypothesised	 that	 these	 two	 proteins	 are	 protective	 in	 the	development	 and	 propagation	 of	 CVD.	 Therefore,	 we	 aimed	 to	 investigate	 the	effect	 of	 loss	 of	 Sirt3	 on	 atherosclerosis,	 endothelial	 dysfunction,	 and	 arterial	thrombosis.	Because	the	role	of	Sirt6	in	endothelial	function	and	atherosclerosis	was	 already	 under	 investigation,	 we	 focused	 on	 determining	 the	 effect	 of	endothelial	specific	loss	of	Sirt6	on	arterial	thrombosis.		
5.1 The	role	of	Sirt3	in	atherothrombosis	
Hypothesis		Loss	 of	 Sirt3	 accelerates	 atherosclerosis,	 causes	 endothelial	 dysfunction,	 and	increases	arterial	 thrombosis	by	 impairing	Sirt3-mediated	anti-oxidant	defence	mechanisms.		
Specific	aims	Sirt3	in	atherosclerosis	a. Characterisation	 of	 the	 effect	 of	 Sirt3	 deficiency	 on	 atherosclerosis	 in	LDL-receptor	knockout	mice	fed	a	high-cholesterol	diet	b. Assessment	of	 the	effect	of	 Sirt3	deficiency	on	 systemic	oxidative	 stress	and	 metabolism	 in	 LDL-receptor	 knockout	 mice	 fed	 a	 high-cholesterol	diet		Sirt3	in	endothelial	function	c. Evaluation	of	the	effect	of	loss	of	Sirt3	on	endothelial	function	in	mice	fed	a	high-cholesterol	diet	d. Unravelling	of	the	molecular	effect	of	Sirt3	deficiency	on	cultured	human	aortic	endothelial	cells		Sirt3	in	arterial	thrombosis	e. Assessment	 of	 the	 effect	 of	 loss	 of	 Sirt3	 on	 arterial	 thrombosis	 in	mice	stressed	with	bacterial	lipopolysaccharide	f. Characterisation	 of	 the	 cell	 type	 and	 mechanism	 by	 which	 Sirt3	 may	influence	arterial	thrombosis			
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5.2 The	role	of	Sirt6	in	arterial	thrombosis	
Hypothesis	Endothelium-specific	loss	of	Sirt6	promotes	thrombosis	by	activating	NF-κB	and	AP-1	mediated	pro-inflammatory	pathways	in	endothelial	cells.		
Specific	aims	a. Generation	 and	 characterisation	 of	 endothelium-specific	 Sirt6	 knockout	mice	b. Evaluation	of	the	effect	of	endothelial	loss	of	Sirt6	on	arterial	thrombosis	c. Assessment	of	 the	molecular	 effects	of	 Sirt6	deficiency	on	human	aortic	endothelial	cells	
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6 Results		
6.1 Deletion	 of	 Sirt3	 does	 not	 affect	 atherosclerosis	 but	 accelerates	
weight	 gain	 and	 impairs	 rapid	 metabolic	 adaptation	 in	 LDL	 receptor	
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Figure S1: Loss of Sirt3 does not increase aortic oxidative DNA damage. 
 
 
 
 
Figure S1: Eight-week old male LDLR-/- and LDLR-/-Sirt3-/- mice were fed a high-
cholesterol diet (1.25% w/w) for 12 weeks before aortae were harvested. Aortic DNA 
was isolated and relative oxidative damage of genomic (A) and mitochondrial DNA 
(B) was assessed using quantitative PCR. (A) Lesion frequency and the resulting 
copy number of ß-Globin served as surrogate for genomic DNA damage. (B) Lesion 
frequency and the resulting copy number of a 117bp mitochondrial DNA fragment 
served as surrogate for mitochondrial DNA damage. Box plots show interquartile 
ranges, whiskers indicate minima and maxima. 
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Figure S2: Loss of Sirt3 does not affect aortic expression levels of major 
NADPH regenerating enzymes. 
 
 
 
Figure S2: Eight-week old male LDLR-/- and LDLR-/- Sirt3-/- mice were fed a high-
cholesterol diet (1.25% w/w) for 12 weeks before mice were harvested and mRNA 
was isolated. Aortic expression analyses of the key NADPH regenerating enzymes 
were assessed using quantitative PCR. (A) Malic enzyme. (B) NADPH 
transhydrogenase. (C) Glucose-6-phosphate dehydrogenase (Glc-6-phosphate 
dehydrogenase). (D) 6-Phosphogluconate dehydrogenase. (E) Isocitrate 
dehydrogenase 2 (IDH2). Box plots show interquartile ranges, whiskers indicate 
minima and maxima. 
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Figure S3: Sirt3 deficiency leads to hepatic global mitochondrial 
hyperacetylation both after high-cholesterol diet and normal chow. 
 
 
 
      
 
Figure S3: Eight-week old male Sirt3-/-, Sirt3-/- LDLR-/-, and wiltdtype mice, 
respectively, were fed a high-cholesterol diet (1.25% w/w) or normal chow for 12 
weeks before mice were harvested. Mitochondrial protein was isolated from livers (A 
& B) and gastrocnemius muscle, respectively, electrophoretically separated and 
probed with anti-acetyl lysine (α-AcK). (A) Hepatic mitochondrial protein acetylation 
after 12 weeks of high-cholesterol diet. (B) Hepatic mitochondrial protein acetylation 
after 12 weeks of normal chow. (C) Gastrocnemic mitochondrial protein acetylation 
after 12 weeks of high-cholesterol diet. ATP-synthase subunit ß (ATPB) served as 
loading control. Data are presented as means ± SEM with superimposition of 
individual data points. 
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Figure S4: Loss of Sirt3 does not affect epididymal white adipose tissue, liver 
or spleen mass in LDLR-/- mice. 
 
 
 
Figure S4: Eight-week old male LDLR-/- and LDLR-/-Sirt3-/- mice were fed a high-
cholesterol diet (1.25% w/w) for 12 weeks before mice were harvested. (A) 
Epididymal white adipose tissue (WAT) mass. (B) Liver mass. (C) Spleen mass. Data 
are presented as means ± SEM with superimposition of individual data points. 
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Figure S5: Loss of Sirt3 does not affect metabolic substrate preference or food 
intake. 
Figure S5: After a 12-week high-cholesterol diet (1.25% w/w) different metabolic 
parameters were assessed in individually-caged LDLR-/- and LDLR-/-Sirt3-/- mice 
during five light cycles. (A) Respiratory quotient averaged per day/night (left panel); 
respiratory quotient drop during fasting, determined by subtracting the individual, fed 
(Night 3) to fasted (Night 4) averages (center panel, « Delta N3 vs. N4 ») and 
respiratory quotient rebound upon refeeding, determined by subtracting refed (Night 
5) to fasted (Night 4) averages (right panel, « Delta N4 vs. N5 »). (B) Cumulative, 
real-time feeding (left panel) and total feeding (right panel) over the whole 
experiment. (C) Body weights before (Day 0), during (Day 3) and after (Day 5) the 
experiment. Data are presented as means ± SEM, with superimposition of individual 
data points in « Delta » panels. N=Night, D=Day. *) p<0.05 compared with LDLR-/-
Sirt3-/- mice. 
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SUPPLEMENTARY METHODS 
 
Tissue harvesting and processing  
Mice were anesthetized using isoflurane. After medial thoraco- and laparotomy the 
left ventricle was punctured and blood was drawn. Thereafter, the right atrium was 
incised and the vascular system was rinsed briefly with cold normal saline (0.9% w/v) 
before organs were explanted. For histological examination, tissue was embedded in 
OCT (optimal cutting temperature) compound (Tissue-Tek) and immediately frozen 
on dry ice; for biochemical analyses samples were snap frozen in liquid nitrogen. All 
samples were stored at -80°C until analysis. 
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Figure	S1	–	Aortic	relaxation	is	endothelium-	and	nitric	oxide	(NO)-dependent	
	
Figure	 S1	 –	 Relaxation	 of	 aortic	 rings	 from	 wild-type	 and	 Sirt3-/-	 mice	 in	response	 to	 sodium	nitroprusside	 (SNP)	 following	 a	 normal	 diet	 (A)	 or	 a	 high	cholesterol	diet	(B).	(C)	Relaxation	of	aortic	rings	from	wild-type	and	Sirt3-/-	mice	fed	a	normal	diet	in	response	to	acetylcholine	(ACh)	after	preincubation	with	L-nitroarginine	 methyl	 ester	 (L-NAME),	 an	 inhibitor	 of	 endothelial	 nitric	 oxide	synthase.	 n	 =	 9	 to	 11	 per	 group,	 quantification	 of	 the	 areas	 under	 the	 curve	(AUC),	 boxplots	 show	 interquartile	 ranges,	 whiskers	 indicate	 minima	 and	maxima.	 	
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Figure	S2	–	Body	weight	does	not	differ	between	Sirt3-/-	and	wildtype	controls	
	
	
	
Figure	 S2	 –	 (A)	 Body	 weights	 of	wild-type	 and	 Sirt3-/-	 mice	 before	 subjecting	them	to	organ	chamber	experiments.	 	
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Figure	S3	–	Expression	of	glutathione	peroxidase,	xanthine	oxidase,	thioredoxin	1	
and	 2,	 and	 thioredoxin-dependent	 peroxide	 reductase	 are	 unaltered	 following	
transient	knockdown	of	Sirt3 	
		
Figure	 S3	 –	 Expression	 analyses	 of	 (A)	 glutathione	 peroxidase,	 (B)	 xanthine	oxidase,	 (C)	 thioredoxin	 1,	 (D)	 thioredoxin	 2,	 (E)	 thioredoxin-dependent	peroxide	 reductase	 (PRDX3),	 and	 (F,	 G)	 NADPH	 oxidase	 subunits	 p47phox	 and	p22phox	 in	HAEC	following	transient	knockdown	of	Sirt3,	using	quantitative	PCR	(A,	C-G	 left	panel)	and	western	blot	analysis	 (B,	G	right	panel),	 respectively.	At	least	 three	 independent	 experiments	 in	 biological	 triplicates	 were	 performed.	Scr	=	scrambled	control.		 	
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Figure	S4	–	Nitric	oxide	(NO)	generation	is	not	affected	by	Sirt3	deficiency	
	
Figure	 S4	 –	 Expression	 analyses	 (western	 blot)	 of	 (A)	 total	 eNOS,	 (B)	 eNOS	phosphorylated	 at	 serine	 1177	 (p-eNOS(Ser1177)),	 and	 (C)	 eNOS	phosphorylated	at	 threonine	495	 (p-eNOS(Thr495))	 in	HAEC	upon	knockdown	of	 Sirt3	 or	 control	 transfection	 using	 scrambled	 siRNA	 (scr).	 (D)	Western	 blot	analyses	of	eNOS	un-/coupling	upon	knockdown	of	Sirt3	or	control	transfection	using	scrambled	siRNA	(scr).	(E)	Nitric	oxide	production	using	DAF-2	diacetate	in	HAEC	upon	knockdown	of	Sirt3,	 control	 transfection	using	scrambled	siRNA	(scr)	 or	 non-transfected	 (NT)	 controls.	 Each	 condition	 was	 assessed	 with	 or	without	 (vehicle)	 L-NIO,	 a	 non-selective	 nitric	 oxide	 synthase	 inhibitor.	 ***)	p<0.001,	 **)	 p<0.01,	 n.s.	 =	 not	 significant.	 Boxpots	 show	 interquartile	 ranges,	whiskers	indicate	minima	and	maxima.		 	
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Figure	S5	–	Loss	of	SOD2	induces	transcription	of	C/EBP-ß		
		
Figure	 S5	 –	 Expression	 analyses	 using	 quantitative	 PCR	 (left	 hand	 side)	 and	western	blot	analysis	(right	hand	side)	of	SOD2	(A,	B),	C/EBP-ß	(C,	D),	and	Sirt3	(F,	 G)	 of	 HAEC	 following	 transient	 knockdown	 of	 SOD2	 (siSOD2)	 or	 control	transfection	with	scrambled	siRNA	(scr).	At	least	three	independent	experiments	in	biological	triplicates	were	performed.	
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6.3 Loss	of	 Sirt3	 accelerates	 arterial	 thrombosis	by	 increasing	 formation	
of	neutrophil	extracellular	traps	and	plasma	tissue	factor	activity		
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7 Discussion	
7.1 Main	findings	In	the	first	part	of	this	dissertation,	we	investigated	the	effects	of	a	global	Sirt3	deletion	 in	a	mouse	model	 in	atherosclerosis,	endothelial	 function,	and	arterial	thrombosis.	 We	 hypothesised	 that	 Sirt3	 deletion	 accelerates	 atherosclerosis,	induces	endothelial	dysfunction	and	enhances	thrombosis	due	to	an	increase	in	oxidative	stress.	In	 the	 second	 part,	 we	 focused	 on	 the	 role	 of	 Sirt6	 in	 thrombosis.	 We	hypothesised	 that	 Sirt6	 depletion	 in	 the	 endothelium	 increases	 arterial	thrombosis	 through	 the	 activation	 of	 NF-κB	 and	 AP-1	 pro-inflammatory	pathways	in	the	endothelium.		
Sirt3	in	atherosclerosis	To	assess	the	effects	of	Sirt3	in	atherosclerosis,	we	generated	Sirt3-/-	mice	on	the	background	of	an	LDL-R	knockout	atherosclerotic	mouse	model	and	fed	them	a	high-cholesterol	 diet	 for	 12	 weeks	 to	 induce	 atherosclerosis.	 Interestingly,	although	 levels	 of	 the	 systemic	 oxidative	 stress	marker	malondialdehyde	were	increased	 in	 these	 mice	 (Figure	 11),	 deletion	 of	 Sirt3	 did	 not	 affect	 plaque	burden,	fibrous	cap	thickness,	necrotic	core	diameter,	or	plaque	macrophage	and	T-cell	 infiltration.	However,	 loss	 of	 Sirt3	was	 coupled	 to	 an	 accelerated	weight	gain	and	impaired	capability	to	cope	with	rapid	changes	in	nutrient	supply.		
Sirt3	in	endothelial	function	Secondly,	 we	 fed	 Sirt3-/-	 mice	 a	 high-cholesterol	 diet	 for	 12	 weeks	 and	subsequently	 evaluated	 endothelial	 function.	 We	 showed	 that	 Sirt3	 deficiency	blunts	 SOD2	 activity	 and	 increases	 levels	 of	 superoxide	 in	 endothelial	 cells	 in	
vitro.	However,	 endothelial	 function	assessed	by	 aortic	 relaxation	 capacity	was	only	mildly	impaired	in	Sirt3-/-	mice	(Figure	11).	Supplementing	the	aortae	with	pegylated	SOD,	rescued	the	impaired	relaxation	capacity.	As	a	potential	cause	for	the	mild	effect,	we	identified	a	novel	C/EBP-β-dependent	feedback	upregulation	of	 SOD2,	 which	 is	 able	 to	 protect	 the	 endothelium	 from	 oxidative	 stress	 in	absence	 of	 Sirt3.	 Inactivating	 this	 rescue	mechanism	 enhanced	 endothelial	 cell	death.				
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Sirt3	in	arterial	thrombosis	Furthermore,	 we	 tested	 the	 effect	 of	 Sirt3	 deficiency	 on	 laser-induced	 arterial	thrombosis	in	Sirt3-/-	mice	stimulated	with	LPS.	Time	to	thrombotic	occlusion	in	these	mice	was	 reduced	by	half	 compared	 to	 the	control	group.	Moreover,	 clot	formation	 was	 accelerated	 and	 clot	 stability	 increased.	 We	 discovered	 higher	levels	 of	 circulating	 TF	 in	 the	 plasma	 and	 an	 increased	NET	 formation	 rate	 in	Sirt3-deficient	neutrophils	as	reasons	for	accelerated	thrombosis	(Figure	11).	In	line	with	 this	 observation,	 transcription	 of	 SOD2	 in	murine	 Sirt3-/-	 neutrophils	was	decreased	and	leukocytes	of	patients	showed	a	reduction	in	SOD2,	as	well	as	Sirt3,	after	STEMI.	
Figure	 11.	 The	 effects	 of	 global	 loss	 of	 Sirt3	 and	 endothelial	 loss	 of	 Sirt6	 on	 the	
vasculature.	Left:	Global	loss	of	Sirt3	leads	to	increased	systemic	reactive	oxygen	species	(ROS),	increased	 levels	 of	 circulating	 soluble	 tissue	 factor	 (TF)	 and	 increased	 formation	of	 neutrophil	extracellular	traps	(NETs).	Furthermore,	ROS	in	endothelial	mitochondria	is	increased.	All	these	changes	lead	to	endothelial	dysfunction	and	accelerated	arterial	thrombosis.	Atherosclerosis	was	not	affected	by	Sirt3	deficiency	in	our	setting.	Right:	Endothelium-specific	deletion	of	Sirt6	leads	to	accelerated	thrombosis	via	increased	TF	expression	and	inflammatory	signalling	in	endothelial	cells.	
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Sirt6	in	arterial	thrombosis	Finally,	 we	 analysed	 the	 effect	 of	 endothelium-specific	 Sirt6	 deficiency	 on	arterial	 thrombosis.	 Time	 to	 thrombotic	 occlusion	 in	 endothelial	 Sirt6-/-	 mice	occurred	 45%	 faster	 compared	 to	 control	 mice,	 after	 inducing	 arterial	thrombosis	with	 a	 laser.	 In	vitro,	 Sirt6-deficient	HAECs	 exhibited	 increased	 TF	transcription,	 protein	 expression	 and	 activity,	 along	 with	 transcriptional	upregulation	of	pro-inflammatory	cytokines	that	are	induced	by	NF-κB	and	AP-1	transcription	factors	(Figure	11).		
7.2 Key	findings	in	comparison	to	current	literature	
Added	value	of	our	Sirt3	loss-of-function	data	Opposing	 our	 hypothesis,	 Sirt3	 deficiency	 did	 not	 affect	 atherosclerosis	 and	induced	only	mild	endothelial	dysfunction,	although	we	could	prove	that	loss	of	Sirt3	 is	 increasing	 oxidative	 stress	 systemically	 and	 in	 endothelial	 cells.	 We	identified	 a	 novel	 C/EBP-β-dependent	 feedback	mechanism	 that	 explains	 how	the	 endothelium	 is	 protected	 from	 ROS-induced	 endothelial	 dysfunction.	 The	same	mechanism	could	explain	a	 lack	of	difference	between	Sirt3-/-	and	control	mice	 in	 atherosclerosis:	 when	 Sirt3	 is	 lacking,	 the	 compensatory	 mechanism	protects	 the	 endothelium	 from	 dysfunction,	 which	 prevents	 increased	 cellular	adhesion	 of	 leukocytes	 to	 the	 endothelium	 and	 subsequently	 accelerated	progression	of	atherosclerosis.	Furthermore,	our	findings	show	that	loss	of	Sirt3	on	an	atherogenic	background	impairs	metabolic	adaptation	and	causes	weight	gain.	These	 findings	are	 in	 line	with	previous	ones	that	assigned	Sirt3	a	role	 in	the	development	of	metabolic	syndrome.164		To	 date,	 we	 are	 the	 only	 group	 that	 investigated	 Sirt3	 in	 atherosclerosis	 and	arterial	 thrombosis,	 but	 other	 groups	 also	 examined	 its	 implication	 in	endothelial	function.	A	study,	which	was	published	only	one	month	before	ours,	confirmed	 that	 loss	 of	 Sirt3	 increases	 superoxide	 levels	 in	 endothelial	 cells.201	However,	 as	 opposed	 to	 our	 study,	 Yang	 and	 associates	 showed	 a	 more	pronounced	impairment	of	endothelial	relaxation	capacity	in	Sirt3-/-	mice.	This	is	likely	due	to	the	different	model	they	chose.	First	of	all,	they	used	the	129-mouse	strain	 for	 their	 experiments,	 while	 we	 used	 C57BL/6	 mice.	 The	 strain	 can	immensely	 influence	the	outcome	of	an	experiment.	 Indeed,	a	study	 from	1990	showed,	 that	when	mice	of	16	different	genetic	backgrounds	were	subjected	to	an	atherogenic	diet,	 some	strains,	 including	C57BL/6,	were	very	 susceptible	 to	atherosclerosis,	 while	 others	 were	 completely	 resistant.202	 More	 specifically,	when	comparing	aortic	cross	sections	of	C57BL/6	and	129	mice	after	14	weeks	
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of	atherogenic	diet,	C57BL/6	mice	exhibited	a	mean	lesion	area	of	4200µm2	per	section,	while	129	mice	showed	a	mean	area	of	only	350µm2.	Our	strong	interest	towards	 the	 role	of	Sirt3	 in	atherosclerosis,	 together	with	clear	proof	 from	the	literature,	 stating	 that	 C57BL/6	 background	 is	 among	 the	 best	models	 for	 this	disease,	served	the	basis	for	choosing	these	mice	for	our	projects.	Secondly,	Yang	and	their	team	used	a	different	stimulus	to	activate	the	endothelium.	They	used	a	model	 of	 obesity	 by	 feeding	 their	 mice	 a	 45%	 high-fat	 diet	 for	 24	 weeks,	 in	contrast	 to	 our	 12-week	 1.25%	 high-cholesterol	 diet.	 While	 no	 significant	difference	in	body	weight	between	Sirt3-/-	and	wildtype	could	be	observed	in	our	model,	 the	 weight	 of	 129-Sirt3-/-	 mice	 was	 increased	 by	 26.6%	 compared	 to	respective	 controls.201	 As	 obesity	 presents	 a	 major	 risk	 factor	 for	 endothelial	dysfunction,	it	makes	sense	that	such	a	pronounced	increase	affects	endothelial	function.203		Our	 results	 assessing	 Sirt3	 in	 arterial	 thrombosis	 support	 our	 hypothesis	 and	add	neutrophils	as	new	protagonist	cells	 in	which	Sirt3	plays	a	protective	role.	Since	formation	of	NETs	is	dependent	on	generation	of	ROS,	it	is	likely	that	Sirt3	is	protecting	neutrophils	from	NET	release	by	mediating	ROS	via	SOD2	and	CAT,	as	previously	described	in	other	contexts.161-163	Interestingly,	a	recent	discovery	associated	loss	of	Sirt3	with	an	impaired	recovery	after	myocardial	ischaemia.204	Taking	 into	 account	 the	 detrimental	 role	 of	 NETs	 after	 reperfusion,	 increased	formation	 of	 NETs	 may	 explain	 why	 the	 recovery	 after	 ischaemia	 in	 Sirt3-deficient	mice	is	impaired.129		
Added	value	of	our	Sirt6	loss-of-function	data	The	second	proposed	hypothesis,	stating	that	endothelium-specific	 loss	of	Sirt6	increases	thrombosis	via	activation	of	NF-κB	and	AP-1	pathways,	was	verified	by	our	 results.	 However,	 since	 it	 is	 still	 work	 in	 progress,	 we	 cannot	 confidently	conclude	 if	 or	which	of	 the	 two	pro-inflammatory	 transcription	 factors	plays	 a	more	pronounced	role	in	thrombosis	induced	by	endothelial	Sirt6	deficiency.	All	the	identified	upregulated	pro-inflammatory	targets	can	be	controlled	by	NF-κB	and	AP-1.	 To	 date,	 there	 are	 no	 publications	 dealing	with	 Sirt6	 in	 thrombosis.	However,	a	role	for	Sirt6	in	endothelial	dysfunction	and	atherosclerosis	has	been	described.199,200,205,206	 Since	 these	 studies	 specifically	 investigated	 endothelial	cells,	the	results	can	be	well	compared	to	our	findings.	It	has	been	demonstrated	
in	 vitro	 that	 human	 umbilical	 vein	 endothelial	 cells	 lacking	 Sirt6	 show	 a	 pro-inflammatory	 phenotype	 with	 an	 increase	 in	 expression	 of	 cell	 adhesion	
 79	
molecules.200,205	These	observations	were	likely	triggered	by	an	increase	in	NF-
κB	expression	and	signalling	and	are	in	line	with	our	results.200		On	 the	 other	 hand,	 one	 of	 the	 studies	 also	 showed	 an	 increase	 in	 pro-inflammatory	 interleukins	 (IL)	 1β,	 6	 and	 8,	 which	 is	 something	 we	 could	 not	observe.200	 In	 fact,	 our	 findings	 suggest,	 that	 transcription	 of	 IL-6	 and	 IL-8	 is	downregulated	in	Sirt6-deficient	cells.	The	main	reason	for	the	difference	may	be	that	in	the	published	study,	LPS	is	used	to	stimulate	endothelial	cells.	The	use	of	this	bacterial	endotoxin	may	trigger	an	 increased	release	of	 interleukins	that	 is	even	more	 pronounced	 in	 the	 absence	 of	 Sirt6.	 Furthermore,	 we	 used	 human	aortic	endothelial	 cells,	whereas	our	colleagues	used	umbilical	vein	endothelial	cells.	 It	 cannot	 be	 excluded,	 that	 Sirt6	 plays	 different	 regulatory	 roles	 in	 the	different	cell	 types.	Finally,	 in	vivo	 studies	using	heterozygous	deletion	or	gene	knockdown	of	Sirt6	on	an	atherosclerotic	background	sustain	our	findings,	that	VCAM-1	and	ICAM-1	are	upregulated	in	the	absence	of	Sirt6.199,206		
7.3 Potential	limitations	As	already	described,	Sirt3	deficiency	per	se	 is	not	sufficient	to	 induce	a	strong	phenotype	 in	mice,	 unless	 the	 system	 is	 challenged	 by	 another	 stimulus.148,150	For	 our	 studies	 of	 atherosclerosis	 and	 endothelial	 function	 we	 chose	 a	 high-cholesterol	diet	as	a	stimulus	because	it	induces	atherosclerosis	and	activates	the	endothelium.	This	diet	may	have	blunted	the	effect	of	Sirt3	in	control	mice,	as	the	activity	 of	 all	 sirtuins	 is	 inhibited	 upon	 caloric	 excess.	 However,	 a	 complete	inhibition	 of	 Sirt3	 is	 highly	 unlikely,	 since	 our	 analyses	 showed	 less	 global	mitochondrial	acetylation	in	controls	compared	to	Sirt3-depleted	mice.		In	the	endothelial	function	study,	we	used	a	high-cholesterol	diet	in	Sirt3-/-	mice	with	 intact	 LDL-R.	 Studies	 investigating	 hypercholesterolemia	 in	mice	 showed	that	 LDL-R+/+	 mice	 did	 not	 have	 increased	 cholesterol	 levels	 when	 fed	 a	moderate	 cholesterol	 diet.207	 This	 indicates	 that	 Sirt3-/-	 mice	 may	 still	 cope	rather	 well	 with	 the	 high-cholesterol	 diet	 and	 possibly	 suffer	 merely	 from	moderate	stress.	Our	findings	show	that	ROS	that	is	induced	by	this	stress	can	be	scavenged	 via	 a	 feedback-upregulation	 of	 SOD2	 in	 endothelial	 cells.	 Taken	together,	 these	 findings	 suggest	 that	 feeding	 a	 high-cholesterol	 diet	 may	 have	been	 too	 weak	 of	 a	 stimulus	 to	 induce	 a	 Sirt3-mediated	 change	 in	 the	endothelium.		
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A	 stronger	 stressor	 was	 used	 to	 assess	 the	 function	 of	 Sirt3	 in	 arterial	thrombosis.	 Sirt3-/-	 mice	were	 stimulated	with	 LPS,	 a	 bacterial	 endotoxin	 that	activates	leukocytes	and	triggers	formation	of	ROS.208	LPS	may	not	be	occurring	in	 all	 cases	 of	 atherothrombosis	 and	 classically	 this	 disease	 is	 seen	 as	 a	 non-infectious	inflammatory	disease.	Nevertheless,	there	are	studies	challenging	this	view	 by	 associating	 the	 gut	 microbiome	 with	 cardiovascular	 diseases	 and	neutrophil	ageing,	indicating	that	endogenous	bacterial	endotoxins	play	a	role	in	CVD.209,210	 Furthermore,	 neutrophil	 activation	 can	 also	 be	 triggered	 by	 the	activated	endothelium	and	platelets,	indicating	that	a	pathogenic	stimulus	is	not	necessary	to	induce	neutrophil	reactions	in	atherothrombosis.111,112		As	Sirt6	deficiency	has	a	much	stronger	effect	in	mice	than	deletion	of	Sirt3,	no	additional	 stimulus	 was	 used	 for	 these	 experiments.	 We	 generated	 an	endothelium-specific	 knockout	 of	 Sirt6	 to	 assess	 the	 function	 of	 this	 nuclear	sirtuin	 in	 thrombosis.	 In	 earlier	 studies,	 Cre-recombinase	 expressed	 under	 the	Tie2	promoter	was	used	to	achieve	an	endothelium-specific	deletion.	It	was	later	shown,	 however,	 that	 Tie2	 is	 also	 expressed	 in	 monocytes/macrophages,	indicating	that	Tie2-mediated	knockouts	were	not	specific	to	the	endothelium.211	Consequently,	we	employed	a	model	that	deleted	exons	of	Sirt6	by	use	of	a	Cre-recombinase,	 expressed	 under	 the	 vascular	 endothelial	 Cadherin	 (VE-Cadh)	promoter,	 which	 is	 currently	 thought	 of	 as	 the	 best	 method	 to	 achieve	 an	endothelial	knockout.212	Yet,	it	may	be	possible	that	other	cell	types	also	express	VE-Cadh.	 Furthermore,	 in	 the	 current	 state	 of	 the	 project,	 it	 is	 not	 completely	clear,	if	the	generated	Sirt6	knockout	really	worked	as	we	anticipated.	Additional	studies	to	characterise	and	prove	the	endothelial	deletion	of	Sirt6	are	necessary.		A	more	general	limitation	of	our	study	may	be	the	age	of	the	experimental	mice.	We	used	relatively	young	mice	for	our	studies,	whereas	CVD	in	humans	usually	develops	 over	 long	 time	 periods	 and	 thus	 leads	 to	 complications	 only	 in	 aged	individuals.	Hence,	the	results	may	not	be	representative	of	the	events	in	an	aged	organism.	In	fact,	in	an	aged	mouse,	more	pronounced	effects	of	loss	of	Sirt3	or	Sirt6	in	atherothrombosis	may	be	expected.			Finally,	we	 only	 used	male	mice	 in	 our	 studies,	which	may	 limit	 the	 extent	 to	which	the	results	are	relevant	to	females.		
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7.4 Implications	and	outlook	
Sirt3	reduces	chances	of	cardiovascular	risk	factor	development	Even	though	Sirt3	does	not	appear	to	affect	atherosclerotic	plaques,	we	showed	that	 Sirt3-deficient	 mice	 on	 an	 atherosclerotic	 background	 have	 difficulties	 in	maintaining	metabolic	homeostasis	and	show	accelerated	gain	of	weight.	As	both	metabolic	disorders	and	obesity	are	major	risk	factors	for	CVD,	Sirt3	may	play	an	important	role	in	the	prevention	of	cardiovascular	risk	factor	development.143,203	This	does	not	affect	atherosclerosis	immediately,	but	over	time.	Thus,	for	future	studies	 of	 Sirt3	 in	 atherosclerosis,	 it	 would	 be	 interesting	 to	 use	 aged	 Sirt3-deficient	 mice.	 To	 additionally	 reduce	 a	 possible	 blunting	 effect	 of	 a	 high	energetic	 diet,	 such	 as	 high-cholesterol	 diet,	 on	 the	 sirtuins,	 the	 LDL-R-/-/ApoB100	mouse	model	of	atherosclerosis	could	be	used.	 In	this	mouse	model,	the	capability	of	mice	to	edit	apolipoprotein	B	(apoB)	mRNA	is	impaired,	so	they	can	 only	 synthesise	 apoB100,	 which	 remarkably	 increases	 LDL	 levels	 and	induces	 severe	 atherosclerosis	 in	 animals	on	a	normal	 chow	diet.213	 Finally,	 as	our	 results	 revealed,	 Sirt3-/-	 mice	 have	 problems	 to	 adapt	 to	 fast	 changing	nutrient	supply.	This	finding	could	be	used	to	induce	additional	stress	by	fasting	the	mice	once	or	in	cycles,	before	analyses.		
Sirt3	protects	the	endothelium	from	mitochondrial	ROS	Our	 results	 provide	 insights	 into	 a	 novel	 rescue	 mechanism	 that	 protects	endothelial	cells	from	ROS	in	absence	of	Sirt3.	This	highlights	the	importance	of	ROS	 scavenging	 in	 the	 vasculature.	 As	mentioned	 above,	 we	may	 have	 used	 a	relatively	weak	stressor	in	our	system.	Using	a	stronger	stimulus,	as	was	done	by	another	 group,	 affected	 endothelial	 function	 in	 Sirt3-/-	 animals	 to	 a	 greater	extent,	compared	to	our	model.201	We	can	conclude	that	Sirt3	plays	a	protective	role	 in	 the	 endothelium.	 For	 future	 research,	 it	 would	 be	 interesting	 to	 see,	 if	Sirt3	 overexpression	 preserves	 endothelial	 function	 in	 mice.	 Furthermore,	diabetes	 is	 a	 major	 risk	 factor	 for	 endothelial	 dysfunction.214	 Since	 several	studies	 linked	Sirt3	 to	 the	 regulation	of	 insulin	 sensitivity	 and	protection	 from	insulin	resistance,	it	would	be	particularly	interesting	to	investigate	endothelial	function	in	Sirt3-deficient	diabetic	mice.156,201,215		
Sirt3	regulates	NET	formation	As	 described,	 NETs	 are	 implicated	 in	 a	wide	 range	 of	 diseases,	 including	 CVD.	Investigating	arterial	 thrombosis,	our	 findings	demonstrate	that	Sirt3	 is	able	to	prevent	NET	formation	in	neutrophils.	Thus,	activation	of	Sirt3	may	reduce	NET	
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formation	in	disease	contexts	and	improve	patient	outcome.	However,	it	remains	elusive	 whether	 this	 would	 also	 affect	 neutrophil	 anti-infectious	 mechanisms.	Yet,	 it	 could	 be	 studied	 using	 a	 neutrophil-specific	 Sirt3	 overexpression	approach.	 Sirt3	 could	 be	 overexpressed	 under	 the	 promoters	 of	 neutrophil-specific	CD18	 integrin	or	myeloid-related	protein	8,	 as	used	before	 for	 specific	knockout	approaches.216,217		
Sirt6	protects	the	endothelium	from	inflammation	and	a	pro-thrombotic	state	Our	 further	 studies	 uncovered	 a	 beneficial	 role	 of	 Sirt6	 in	 arterial	 thrombosis	and	suggest	that	Sirt6	delays	thrombosis	by	protecting	the	endothelium.	It	would	be	interesting	to	assess	if	Sirt6	can	do	this	more	efficiently	when	it	is	activated	or	overexpressed	in	the	endothelium.		While	Sirt6-dependent	retention	of	NF-κB	and	AP-1	signalling	is	in	the	centre	of	attention,	 the	 exact	 underlying	 mechanism	 remains	 unclear.	 Histone	 3	acetylation	levels	should	be	assessed,	along	with	functional	studies	of	NF-κB	and	AP-1	 DNA	 binding	 activity.	 ELISA-based	 activity	 assays,	 that	 can	 quantify	 the	amounts	 of	 Sirt6-interaction	 partners	 RelA	 and	 c-JUN	 bound	 to	 DNA,	 are	available.	Alternatively,	phosphorylation	of	c-JUN	and	the	translocation	of	NF-κB	to	the	nucleus	could	shed	light	on	which,	if	only	one	of	the	transcription	factors	is	playing	 a	 predominant	 role.	 Finally,	 the	 results	 obtained	 in	 cell	 cultures	 of	HAECs,	using	a	Sirt6	knockdown	approach,	 should	be	verified	 in	Sirt6-/-	mouse	endothelial	cells.			
7.5 Conclusions	For	 the	 first	 time,	we	describe	a	beneficial	 role	 for	Sirt3	 in	major	hallmarks	of	CVD,	 comprising	 risk	 factor	 development,	 endothelial	 dysfunction,	 and	 arterial	thrombosis,	 and	 an	 advantageous	 role	 for	 endothelial	 Sirt6	 in	 arterial	thrombosis.	Furthermore,	our	results	emphasise	the	detrimental	role	of	ROS	and	inflammatory	signalling	in	these	diseases.		Based	on	our	results,	we	speculate	that	specific	activation	of	Sirt3	and	Sirt6	aids	in	 the	 prevention	 and	 acute	 therapy	 of	 CVD.	 Currently,	 no	 sirtuin-specific	activators	 are	 known.	 Investing	 in	 the	 discovery	 of	 new	 substances	 that	 can	specifically	activate	certain	sirtuins	could	open	a	whole	new	field	of	therapeutic	possibilities	for	CVD,	as	well	as	other	metabolic	and	age-related	diseases.		 	
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